false
Q3
--12-31
0000771999
P1Y
0000771999
2024-01-01
2024-09-30
0000771999
2024-11-11
0000771999
2024-09-30
0000771999
2023-12-31
0000771999
2024-07-01
2024-09-30
0000771999
2023-07-01
2023-09-30
0000771999
2023-01-01
2023-09-30
0000771999
DSS:PrintedProductsMember
2024-07-01
2024-09-30
0000771999
DSS:PrintedProductsMember
2023-07-01
2023-09-30
0000771999
DSS:PrintedProductsMember
2024-01-01
2024-09-30
0000771999
DSS:PrintedProductsMember
2023-01-01
2023-09-30
0000771999
DSS:RentalIncomeMember
2024-07-01
2024-09-30
0000771999
DSS:RentalIncomeMember
2023-07-01
2023-09-30
0000771999
DSS:RentalIncomeMember
2024-01-01
2024-09-30
0000771999
DSS:RentalIncomeMember
2023-01-01
2023-09-30
0000771999
DSS:NetInvestmentIncomeMember
2024-07-01
2024-09-30
0000771999
DSS:NetInvestmentIncomeMember
2023-07-01
2023-09-30
0000771999
DSS:NetInvestmentIncomeMember
2024-01-01
2024-09-30
0000771999
DSS:NetInvestmentIncomeMember
2023-01-01
2023-09-30
0000771999
DSS:DirectMarketingMember
2024-07-01
2024-09-30
0000771999
DSS:DirectMarketingMember
2023-07-01
2023-09-30
0000771999
DSS:DirectMarketingMember
2024-01-01
2024-09-30
0000771999
DSS:DirectMarketingMember
2023-01-01
2023-09-30
0000771999
DSS:CommissionRevenueMember
2024-07-01
2024-09-30
0000771999
DSS:CommissionRevenueMember
2023-07-01
2023-09-30
0000771999
DSS:CommissionRevenueMember
2024-01-01
2024-09-30
0000771999
DSS:CommissionRevenueMember
2023-01-01
2023-09-30
0000771999
2022-12-31
0000771999
2023-09-30
0000771999
us-gaap:CommonStockMember
2022-12-31
0000771999
us-gaap:PreferredStockMember
2022-12-31
0000771999
us-gaap:AdditionalPaidInCapitalMember
2022-12-31
0000771999
us-gaap:RetainedEarningsMember
2022-12-31
0000771999
us-gaap:ParentMember
2022-12-31
0000771999
us-gaap:NoncontrollingInterestMember
2022-12-31
0000771999
us-gaap:CommonStockMember
2023-12-31
0000771999
us-gaap:PreferredStockMember
2023-12-31
0000771999
us-gaap:AdditionalPaidInCapitalMember
2023-12-31
0000771999
us-gaap:RetainedEarningsMember
2023-12-31
0000771999
us-gaap:ParentMember
2023-12-31
0000771999
us-gaap:NoncontrollingInterestMember
2023-12-31
0000771999
us-gaap:CommonStockMember
2023-01-01
2023-09-30
0000771999
us-gaap:PreferredStockMember
2023-01-01
2023-09-30
0000771999
us-gaap:AdditionalPaidInCapitalMember
2023-01-01
2023-09-30
0000771999
us-gaap:RetainedEarningsMember
2023-01-01
2023-09-30
0000771999
us-gaap:ParentMember
2023-01-01
2023-09-30
0000771999
us-gaap:NoncontrollingInterestMember
2023-01-01
2023-09-30
0000771999
us-gaap:CommonStockMember
2024-01-01
2024-09-30
0000771999
us-gaap:PreferredStockMember
2024-01-01
2024-09-30
0000771999
us-gaap:AdditionalPaidInCapitalMember
2024-01-01
2024-09-30
0000771999
us-gaap:RetainedEarningsMember
2024-01-01
2024-09-30
0000771999
us-gaap:ParentMember
2024-01-01
2024-09-30
0000771999
us-gaap:NoncontrollingInterestMember
2024-01-01
2024-09-30
0000771999
us-gaap:CommonStockMember
2023-09-30
0000771999
us-gaap:PreferredStockMember
2023-09-30
0000771999
us-gaap:AdditionalPaidInCapitalMember
2023-09-30
0000771999
us-gaap:RetainedEarningsMember
2023-09-30
0000771999
us-gaap:ParentMember
2023-09-30
0000771999
us-gaap:NoncontrollingInterestMember
2023-09-30
0000771999
us-gaap:CommonStockMember
2024-09-30
0000771999
us-gaap:PreferredStockMember
2024-09-30
0000771999
us-gaap:AdditionalPaidInCapitalMember
2024-09-30
0000771999
us-gaap:RetainedEarningsMember
2024-09-30
0000771999
us-gaap:ParentMember
2024-09-30
0000771999
us-gaap:NoncontrollingInterestMember
2024-09-30
0000771999
DSS:SharingServicesGlobalCorpMember
2023-05-04
2023-05-04
0000771999
DSS:SharingServicesGlobalCorpMember
2023-05-04
0000771999
2023-05-04
2023-05-04
0000771999
DSS:SharingServicesGlobalCorpMember
2023-12-31
0000771999
DSS:CustomerOneMember
us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
2024-01-01
2024-09-30
0000771999
DSS:CustomerTwoMember
us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
2024-01-01
2024-09-30
0000771999
DSS:CustomerOneMember
us-gaap:AccountsReceivableMember
us-gaap:CustomerConcentrationRiskMember
2024-01-01
2024-09-30
0000771999
DSS:CustomerTwoMember
us-gaap:AccountsReceivableMember
us-gaap:CustomerConcentrationRiskMember
2024-01-01
2024-09-30
0000771999
DSS:CustomerOneMember
us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
2023-01-01
2023-09-30
0000771999
DSS:CustomerOneMember
us-gaap:AccountsReceivableMember
us-gaap:CustomerConcentrationRiskMember
2023-01-01
2023-09-30
0000771999
DSS:CustomerTwoMember
us-gaap:AccountsReceivableMember
us-gaap:CustomerConcentrationRiskMember
2023-01-01
2023-09-30
0000771999
DSS:CustomerOneMember
us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
2023-01-01
2023-12-31
0000771999
DSS:CustomerTwoMember
us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
2023-01-01
2023-12-31
0000771999
DSS:CustomerOneMember
us-gaap:AccountsReceivableMember
us-gaap:CustomerConcentrationRiskMember
2023-01-01
2023-12-31
0000771999
DSS:CustomerTwoMember
us-gaap:AccountsReceivableMember
us-gaap:CustomerConcentrationRiskMember
2023-01-01
2023-12-31
0000771999
DSS:PremierSubsidiaryMember
2024-09-30
0000771999
DSS:PremierSubsidiaryMember
2023-12-31
0000771999
stpr:UT
2024-06-30
0000771999
DSS:AMRELifeCarePortfolioLLCMember
2024-09-30
0000771999
DSS:AMREWinterHavenLLCMember
2024-09-30
0000771999
2023-01-01
2023-12-31
0000771999
DSS:PremierPackagingCompanyMember
2024-09-30
0000771999
DSS:ImpactBioMedicalMember
2024-09-30
0000771999
DSS:AmericanPacificBancorpMember
2023-12-31
0000771999
DSS:SentinelCompanyMember
2023-12-31
0000771999
us-gaap:EmployeeStockOptionMember
2023-07-01
2023-09-30
0000771999
us-gaap:EmployeeStockOptionMember
2023-01-01
2023-09-30
0000771999
us-gaap:EmployeeStockOptionMember
2024-07-01
2024-09-30
0000771999
us-gaap:EmployeeStockOptionMember
2024-01-01
2024-09-30
0000771999
2023-01-01
2023-06-30
0000771999
2023-06-30
0000771999
srt:ScenarioPreviouslyReportedMember
2023-09-30
0000771999
srt:RevisionOfPriorPeriodReclassificationAdjustmentMember
2023-09-30
0000771999
DSS:RestatementMember
2023-09-30
0000771999
srt:ScenarioPreviouslyReportedMember
2023-01-01
2023-09-30
0000771999
srt:RevisionOfPriorPeriodReclassificationAdjustmentMember
2023-01-01
2023-09-30
0000771999
DSS:RestatementMember
2023-01-01
2023-09-30
0000771999
DSS:NoteOneMember
2021-05-14
0000771999
DSS:NoteOneMember
2021-05-14
2021-05-14
0000771999
DSS:NoteOneMember
2024-09-30
0000771999
DSS:NoteOneMember
2023-12-31
0000771999
DSS:NoteTwoMember
2021-09-23
0000771999
DSS:NoteTwoMember
2023-12-31
0000771999
DSS:NoteThreeMember
srt:MaximumMember
2021-10-25
0000771999
DSS:NoteThreeMember
2021-10-25
0000771999
DSS:NoteThreeMember
2021-10-24
2021-10-25
0000771999
DSS:NoteThreeMember
2022-12-31
0000771999
DSS:NoteFourMember
2021-12-28
0000771999
DSS:NoteFourMember
2021-12-29
2021-12-29
0000771999
DSS:NoteFourMember
2022-12-29
2022-12-29
0000771999
DSS:NoteFourMember
2023-11-27
0000771999
DSS:NoteFourMember
2023-12-31
0000771999
DSS:NoteFiveMember
2022-01-24
0000771999
DSS:NoteFiveMember
2022-01-23
2022-01-24
0000771999
DSS:NoteFiveMember
2024-09-30
0000771999
DSS:NoteFiveMember
2023-12-31
0000771999
DSS:NoteSixMember
2022-03-02
0000771999
DSS:NoteSixMember
2022-03-02
2022-03-02
0000771999
DSS:NoteSixMember
2024-09-30
0000771999
DSS:NoteSixMember
2023-12-31
0000771999
DSS:NoteSevenMember
2022-05-09
0000771999
DSS:NoteSevenMember
2022-05-09
2022-05-09
0000771999
DSS:NoteSevenMember
2024-09-30
0000771999
DSS:NoteSevenMember
2024-12-31
0000771999
DSS:NoteEightMember
2022-08-29
0000771999
DSS:NoteEightMember
2022-08-28
2022-08-29
0000771999
DSS:NoteEightMember
2024-09-30
0000771999
DSS:NoteEightMember
2023-12-31
0000771999
DSS:NoteEightMember
DSS:DSSFinancialManagementIncMember
2022-08-29
0000771999
DSS:NoteNineMember
2023-05-08
0000771999
DSS:NoteNineMember
2024-09-30
0000771999
DSS:NoteNineMember
2023-12-31
0000771999
DSS:NoteNineMember
2023-05-08
2023-05-08
0000771999
DSS:NoteNineMember
2024-06-30
0000771999
DSS:NoteNineMember
DSS:DSSFinancialManagementIncMember
2023-05-08
0000771999
DSS:NoteTenMember
2022-07-26
0000771999
DSS:NoteTenMember
2022-07-25
2022-07-26
0000771999
DSS:NoteTenMember
2024-09-30
0000771999
DSS:NoteTenMember
2024-03-31
0000771999
DSS:NoteTenMember
2023-12-31
0000771999
DSS:NoteTenMember
2023-01-01
2023-12-31
0000771999
DSS:NoteElevenMember
2021-02-19
0000771999
DSS:NoteElevenMember
2021-02-19
2021-02-19
0000771999
DSS:NoteElevenMember
2024-09-30
0000771999
DSS:NoteElevenMember
2023-12-31
0000771999
DSS:NoteElevenMember
2024-06-30
0000771999
DSS:NoteTwelveMember
2023-06-27
0000771999
DSS:NoteTwelveMember
2023-06-27
2023-06-27
0000771999
DSS:NoteThirteenMember
2023-03-31
0000771999
DSS:NoteThirteenMember
2024-09-30
0000771999
DSS:NoteThirteenMember
2023-12-31
0000771999
DSS:NoteThirteenMember
2023-03-31
2023-03-31
0000771999
DSS:NoteThirteenMember
2024-06-30
0000771999
DSS:NoteForteenMember
2024-08-30
0000771999
DSS:NoteForteenMember
2024-09-30
0000771999
DSS:NoteForteenMember
2024-08-19
2024-08-29
0000771999
us-gaap:CashMember
2024-01-01
2024-09-30
0000771999
us-gaap:CashMember
2024-09-30
0000771999
us-gaap:MoneyMarketFundsMember
us-gaap:FairValueInputsLevel1Member
2024-01-01
2024-09-30
0000771999
us-gaap:MoneyMarketFundsMember
us-gaap:FairValueInputsLevel1Member
2024-09-30
0000771999
DSS:MarketableSecuritiesMember
us-gaap:FairValueInputsLevel1Member
2024-01-01
2024-09-30
0000771999
DSS:MarketableSecuritiesMember
us-gaap:FairValueInputsLevel1Member
2024-09-30
0000771999
us-gaap:CashMember
2023-01-01
2023-12-31
0000771999
us-gaap:CashMember
2023-12-31
0000771999
us-gaap:MoneyMarketFundsMember
us-gaap:FairValueInputsLevel1Member
2023-01-01
2023-12-31
0000771999
us-gaap:MoneyMarketFundsMember
us-gaap:FairValueInputsLevel1Member
2023-12-31
0000771999
DSS:MarketableSecuritiesMember
us-gaap:FairValueInputsLevel1Member
2023-01-01
2023-12-31
0000771999
DSS:MarketableSecuritiesMember
us-gaap:FairValueInputsLevel1Member
2023-12-31
0000771999
DSS:LoanMember
2024-01-01
2024-09-30
0000771999
DSS:LoanMember
2023-01-01
2023-09-30
0000771999
DSS:GeneralLoanPortfolioReserveMember
DSS:AmericanPacificBancorpMember
2024-01-01
2024-09-30
0000771999
DSS:GeneralLoanPortfolioReserveMember
DSS:AmericanPacificBancorpMember
2023-01-01
2023-12-31
0000771999
DSS:SpecificLoanReservesMember
DSS:BorrowerThreeMember
2023-01-01
2023-12-31
0000771999
DSS:SpecificLoanReservesMember
DSS:BorrowerThreeMember
2024-01-01
2024-09-30
0000771999
DSS:SpecificLoanReservesMember
DSS:BorrowerOneMember
2023-12-31
0000771999
DSS:SpecificLoanReservesMember
DSS:BorrowerOneMember
2024-09-30
0000771999
DSS:SpecificLoanReservesMember
DSS:BorrowerTwelveMember
2023-12-31
0000771999
DSS:SpecificLoanReservesMember
DSS:BorrowerTwelveMember
2024-09-30
0000771999
DSS:SpecificLoanReservesMember
DSS:BorrowerTenMember
2024-03-31
0000771999
DSS:SpecificLoanReservesMember
DSS:BorrowerThirteenMember
2024-03-31
0000771999
DSS:SpecificLoanReservesMember
DSS:BorrowerEightMember
2024-03-31
0000771999
DSS:SpecificLoanReservesMember
DSS:BorrowerEightMember
2024-09-30
0000771999
DSS:HWHWorldIncMember
DSS:SharingServicesGlobalCorporationMember
2023-07-01
2023-07-01
0000771999
DSS:SharingServicesGlobalCorporationMember
DSS:AmendedAgreementMember
2023-07-01
2023-07-01
0000771999
DSS:SharingServicesGlobalCorporationMember
DSS:AmendedAgreementMember
2023-07-01
2023-09-30
0000771999
DSS:HWHWorldIncMember
2023-07-01
0000771999
DSS:HWHWorldIncMember
2023-07-01
2023-07-01
0000771999
DSS:HWHWorldIncMember
2023-07-01
2023-09-30
0000771999
2024-06-13
2024-06-13
0000771999
DSS:AlsetInternationalLimitedMember
2024-09-30
0000771999
DSS:AlsetInternationalLimitedMember
2024-01-01
2024-09-30
0000771999
DSS:AlsetInternationalLimitedMember
2023-12-31
0000771999
DSS:AlsetInternationalLimitedMember
2023-01-01
2023-09-30
0000771999
DSS:WestParkCapitalIncMember
2020-12-30
2020-12-30
0000771999
DSS:WestParkCapitalIncMember
2023-12-31
0000771999
DSS:WestParkCapitalIncMember
2024-09-30
0000771999
DSS:DSSSecuritiesIncMember
2020-09-10
0000771999
DSS:DSSSecuritiesIncMember
2020-09-09
2020-09-10
0000771999
DSS:BMICapitalInternationalLLCMember
2021-01-01
2021-01-31
0000771999
DSS:BMICapitalInternationalLLCMember
2020-09-10
0000771999
DSS:BMICapitalInternationalLLCMember
2024-01-01
2024-09-30
0000771999
DSS:BMICapitalInternationalLLCMember
2023-01-01
2023-09-30
0000771999
DSS:BioMedTechnologiesAsiaPacificHoldingsLimitedMember
2020-12-18
2020-12-19
0000771999
DSS:BioMedTechnologiesAsiaPacificHoldingsLimitedMember
2020-12-19
0000771999
DSS:PremierPackagingBankOfAmericaNAMember
2021-05-20
0000771999
DSS:PremierPackagingBankOfAmericaNAMember
2024-09-30
0000771999
DSS:PremierPackagingBankOfAmericaNAMember
2023-12-31
0000771999
DSS:PremierPackagingBankOfAmericaNAMember
2024-01-01
2024-09-30
0000771999
DSS:PremierPackagingBankOfAmericaNAMember
2023-01-01
2023-09-30
0000771999
DSS:LoanAgreementMember
DSS:AMRESheltonLLCMember
2021-08-01
0000771999
DSS:LoanAgreementMember
DSS:AMRESheltonLLCMember
2021-07-29
2021-08-01
0000771999
DSS:LoanAgreementMember
DSS:AMRESheltonLLCMember
2024-09-30
0000771999
DSS:FacilityMember
DSS:LoanAgreementMember
DSS:AMRESheltonLLCMember
2021-07-29
2021-08-01
0000771999
us-gaap:LandMember
DSS:LoanAgreementMember
DSS:AMRESheltonLLCMember
2021-07-29
2021-08-01
0000771999
DSS:TenantImprovementsMember
DSS:LoanAgreementMember
DSS:AMRESheltonLLCMember
2021-07-29
2021-08-01
0000771999
us-gaap:OtherIntangibleAssetsMember
DSS:LoanAgreementMember
DSS:AMRESheltonLLCMember
2021-08-01
0000771999
DSS:LoanAgreementMember
DSS:AMRESheltonLLCMember
2024-01-01
2024-06-30
0000771999
DSS:LoanAgreementMember
DSS:AMRESheltonLLCMember
2023-01-01
2023-06-30
0000771999
DSS:BMICLoanMember
2021-10-13
0000771999
DSS:BMICLoanMember
2021-10-13
2021-10-13
0000771999
DSS:BMICLoanMember
2024-09-30
0000771999
DSS:BMICLoanMember
2023-12-31
0000771999
DSS:WilsonLoanMember
2021-10-13
0000771999
DSS:WilsonLoanMember
2021-10-13
2021-10-13
0000771999
DSS:WilsonLoanMember
2024-09-30
0000771999
DSS:WilsonLoanMember
2023-12-31
0000771999
DSS:PinnacleBankMember
DSS:LifeCareAgreementMember
2021-11-02
0000771999
DSS:PinnacleBankMember
DSS:LifeCareAgreementMember
2021-11-01
2021-11-02
0000771999
DSS:FacilityMember
DSS:LifeCareAgreementMember
DSS:PinnacleBankMember
2021-11-01
2021-11-02
0000771999
us-gaap:LandMember
DSS:LifeCareAgreementMember
DSS:PinnacleBankMember
2021-11-01
2021-11-02
0000771999
DSS:SiteImprovementsMember
DSS:LifeCareAgreementMember
DSS:PinnacleBankMember
2021-11-01
2021-11-02
0000771999
DSS:LifeCareAgreementMember
DSS:PinnacleBankMember
srt:MinimumMember
2021-11-02
0000771999
DSS:LifeCareAgreementMember
DSS:PinnacleBankMember
srt:MaximumMember
2021-11-02
0000771999
DSS:LifeCareAgreementMember
DSS:PinnacleBankMember
2024-09-30
0000771999
DSS:PinnacleBankMember
DSS:LifeCareAgreementMember
2023-12-31
0000771999
DSS:PinnacleBankMember
DSS:LifeCareAgreementMember
2024-01-01
2024-09-30
0000771999
DSS:PinnacleBankMember
DSS:LifeCareAgreementMember
2023-01-01
2023-09-30
0000771999
DSS:PinnacleLoanMember
2022-03-17
0000771999
DSS:PinnacleLoanMember
2022-03-16
2022-03-17
0000771999
DSS:FacilityMember
DSS:PinnacleLoanMember
2022-03-16
2022-03-17
0000771999
us-gaap:LandMember
DSS:PinnacleLoanMember
2022-03-16
2022-03-17
0000771999
DSS:SiteAndTenantImprovementsMember
DSS:PinnacleLoanMember
2022-03-16
2022-03-17
0000771999
DSS:PinnacleLoanMember
2024-09-30
0000771999
DSS:PinnacleLoanMember
2023-01-01
0000771999
DSS:PinnacleLoanMember
2023-12-31
0000771999
DSS:PinnacleLoanMember
2024-06-30
0000771999
DSS:PinnacleLoanMember
2024-01-01
2024-09-30
0000771999
DSS:PinnacleLoanMember
2023-01-01
2023-09-30
0000771999
DSS:SecurityAgreementMember
2023-03-30
0000771999
DSS:SecurityAgreementMember
DSS:UnionBankAndTrustCompanyMember
2023-03-30
0000771999
DSS:SecurityAgreementMember
2023-03-30
2023-03-30
0000771999
DSS:SecurityAgreementMember
2024-09-30
0000771999
DSS:SecurityAgreementMember
2023-12-31
0000771999
DSS:SecurityAgreementMember
2024-01-01
2024-09-30
0000771999
DSS:SecurityAgreementMember
2023-01-01
2023-09-30
0000771999
srt:MinimumMember
2024-09-30
0000771999
srt:MaximumMember
2024-09-30
0000771999
DSS:LicenseAgreementMember
DSS:EquivirLicenseMember
2024-09-30
0000771999
DSS:LicenseAgreementMember
DSS:EquivirLicenseMember
2023-12-31
0000771999
DSS:FrankHeuszelMember
DSS:EmploymentAgreementMember
2023-04-10
2023-04-10
0000771999
2024-01-04
2024-01-04
0000771999
us-gaap:ConvertibleCommonStockMember
2023-12-31
0000771999
us-gaap:ConvertibleCommonStockMember
2023-01-01
2023-12-31
0000771999
2024-01-01
2024-06-30
0000771999
DSS:ImpactBioMedicalIncMember
2023-05-10
0000771999
DSS:ImpactBioMedicalIncMember
2023-05-10
2024-11-05
0000771999
DSS:ImpactBioMedicalIncMember
2023-05-11
0000771999
DSS:ImpactBioMedicalIncMember
DSS:PriorToSplitMember
2023-05-11
0000771999
2023-10-31
2023-10-31
0000771999
DSS:DSSBioHealthSecuritiesIncMember
us-gaap:CommonStockMember
2023-10-31
0000771999
DSS:DSSBioHealthSecuritiesIncMember
DSS:SeriesAConvertiblePreferredStockMember
2023-10-31
0000771999
DSS:DSSBioHealthSecuritiesIncMember
us-gaap:CommonStockMember
srt:MaximumMember
2023-10-31
0000771999
DSS:DSSBioHealthSecuritiesIncMember
us-gaap:CommonStockMember
srt:MinimumMember
2023-10-31
0000771999
DSS:ImpactBioMedicalIncMember
2024-09-30
0000771999
DSS:ImpactBioMedicalIncMember
2023-12-31
0000771999
DSS:ImpactBioMedicalIncMember
2024-06-30
0000771999
2023-07-10
0000771999
DSS:ImpactBioMedicalIncMember
2023-07-10
0000771999
DSS:ImpactBioMedicalMember
2023-10-31
2023-10-31
0000771999
DSS:ImpactBioMedicalMember
2022-12-31
0000771999
DSS:ImpactBioMedicalMember
2024-01-01
2024-09-30
0000771999
DSS:ImpactBioMedicalMember
us-gaap:CommonStockMember
2024-01-01
2024-09-30
0000771999
DSS:ImpactBioMedicalMember
DSS:SeriesAConvertiblePreferredStockMember
2023-10-31
2023-10-31
0000771999
DSS:ImpactBioMedicalMember
us-gaap:IPOMember
2024-09-16
2024-09-16
0000771999
DSS:ImpactBioMedicalMember
us-gaap:IPOMember
2024-09-16
0000771999
DSS:ImpactBioMedicalMember
us-gaap:IPOMember
2024-09-30
0000771999
DSS:ImpactBioMedicalMember
us-gaap:IPOMember
2024-01-01
2024-09-30
0000771999
DSS:DirectMarketingMember
2023-01-01
2023-12-31
0000771999
us-gaap:OperatingSegmentsMember
DSS:ProductPackagingMember
2024-07-01
2024-09-30
0000771999
us-gaap:OperatingSegmentsMember
DSS:CommercialBankingMember
2024-07-01
2024-09-30
0000771999
us-gaap:OperatingSegmentsMember
DSS:DirectMarketingOnlineSalesMember
2024-07-01
2024-09-30
0000771999
us-gaap:OperatingSegmentsMember
DSS:BiotechnologyMember
2024-07-01
2024-09-30
0000771999
us-gaap:OperatingSegmentsMember
DSS:SecuritiesMember
2024-07-01
2024-09-30
0000771999
us-gaap:OperatingSegmentsMember
us-gaap:CorporateMember
2024-07-01
2024-09-30
0000771999
us-gaap:OperatingSegmentsMember
2024-07-01
2024-09-30
0000771999
us-gaap:OperatingSegmentsMember
DSS:ProductPackagingMember
2023-07-01
2023-09-30
0000771999
us-gaap:OperatingSegmentsMember
DSS:CommercialBankingMember
2023-07-01
2023-09-30
0000771999
us-gaap:OperatingSegmentsMember
DSS:DirectMarketingOnlineSalesMember
2023-07-01
2023-09-30
0000771999
us-gaap:OperatingSegmentsMember
DSS:BiotechnologyMember
2023-07-01
2023-09-30
0000771999
us-gaap:OperatingSegmentsMember
DSS:SecuritiesMember
2023-07-01
2023-09-30
0000771999
us-gaap:OperatingSegmentsMember
us-gaap:CorporateMember
2023-07-01
2023-09-30
0000771999
us-gaap:OperatingSegmentsMember
2023-07-01
2023-09-30
0000771999
us-gaap:OperatingSegmentsMember
DSS:ProductPackagingMember
2024-01-01
2024-09-30
0000771999
us-gaap:OperatingSegmentsMember
DSS:CommercialBankingMember
2024-01-01
2024-09-30
0000771999
us-gaap:OperatingSegmentsMember
DSS:DirectMarketingOnlineSalesMember
2024-01-01
2024-09-30
0000771999
us-gaap:OperatingSegmentsMember
DSS:BiotechnologyMember
2024-01-01
2024-09-30
0000771999
us-gaap:OperatingSegmentsMember
DSS:SecuritiesMember
2024-01-01
2024-09-30
0000771999
us-gaap:OperatingSegmentsMember
us-gaap:CorporateMember
2024-01-01
2024-09-30
0000771999
us-gaap:OperatingSegmentsMember
2024-01-01
2024-09-30
0000771999
us-gaap:OperatingSegmentsMember
DSS:ProductPackagingMember
2023-01-01
2023-09-30
0000771999
us-gaap:OperatingSegmentsMember
DSS:CommercialBankingMember
2023-01-01
2023-09-30
0000771999
us-gaap:OperatingSegmentsMember
DSS:DirectMarketingOnlineSalesMember
2023-01-01
2023-09-30
0000771999
us-gaap:OperatingSegmentsMember
DSS:BiotechnologyMember
2023-01-01
2023-09-30
0000771999
us-gaap:OperatingSegmentsMember
DSS:SecuritiesMember
2023-01-01
2023-09-30
0000771999
us-gaap:OperatingSegmentsMember
us-gaap:CorporateMember
2023-01-01
2023-09-30
0000771999
us-gaap:OperatingSegmentsMember
2023-01-01
2023-09-30
0000771999
DSS:PackagingPrintingandFabricationMember
DSS:PrintedProductsMember
2024-07-01
2024-09-30
0000771999
DSS:CommercialandSecurityPrintingMember
DSS:PrintedProductsMember
2024-07-01
2024-09-30
0000771999
DSS:PackagingPrintingandFabricationMember
DSS:PrintedProductsMember
2023-07-01
2023-09-30
0000771999
DSS:CommercialandSecurityPrintingMember
DSS:PrintedProductsMember
2023-07-01
2023-09-30
0000771999
DSS:PackagingPrintingandFabricationMember
DSS:PrintedProductsMember
2024-01-01
2024-09-30
0000771999
DSS:CommercialandSecurityPrintingMember
DSS:PrintedProductsMember
2024-01-01
2024-09-30
0000771999
DSS:PackagingPrintingandFabricationMember
DSS:PrintedProductsMember
2023-01-01
2023-09-30
0000771999
DSS:CommercialandSecurityPrintingMember
DSS:PrintedProductsMember
2023-01-01
2023-09-30
0000771999
DSS:DirectMarketingInternetSalesMember
DSS:DirectMarketingMember
2024-07-01
2024-09-30
0000771999
DSS:DirectMarketingInternetSalesMember
DSS:DirectMarketingMember
2023-07-01
2023-09-30
0000771999
DSS:DirectMarketingInternetSalesMember
DSS:DirectMarketingMember
2024-01-01
2024-09-30
0000771999
DSS:DirectMarketingInternetSalesMember
DSS:DirectMarketingMember
2023-01-01
2023-09-30
0000771999
DSS:RentalIncomeMember
DSS:RentalRevenueIncomeMember
2024-07-01
2024-09-30
0000771999
DSS:RentalRevenueIncomeMember
2024-07-01
2024-09-30
0000771999
DSS:RentalIncomeMember
DSS:RentalRevenueIncomeMember
2023-07-01
2023-09-30
0000771999
DSS:RentalRevenueIncomeMember
2023-07-01
2023-09-30
0000771999
DSS:RentalIncomeMember
DSS:RentalRevenueIncomeMember
2024-01-01
2024-09-30
0000771999
DSS:RentalRevenueIncomeMember
2024-01-01
2024-09-30
0000771999
DSS:RentalIncomeMember
DSS:RentalRevenueIncomeMember
2023-01-01
2023-09-30
0000771999
DSS:RentalRevenueIncomeMember
2023-01-01
2023-09-30
0000771999
DSS:CommissionIncomeMember
DSS:CommissionRevenueMember
2024-07-01
2024-09-30
0000771999
DSS:CommissionIncomeMember
DSS:CommissionRevenueMember
2023-07-01
2023-09-30
0000771999
DSS:CommissionIncomeMember
DSS:CommissionRevenueMember
2024-01-01
2024-09-30
0000771999
DSS:CommissionIncomeMember
DSS:CommissionRevenueMember
2023-01-01
2023-09-30
0000771999
DSS:NetInvestmentIncomeMember
DSS:NetInvestmentRevenueIncomeMember
2024-07-01
2024-09-30
0000771999
DSS:NetInvestmentRevenueIncomeMember
2024-07-01
2024-09-30
0000771999
DSS:NetInvestmentIncomeMember
DSS:NetInvestmentRevenueIncomeMember
2023-07-01
2023-09-30
0000771999
DSS:NetInvestmentRevenueIncomeMember
2023-07-01
2023-09-30
0000771999
DSS:NetInvestmentIncomeMember
DSS:NetInvestmentRevenueIncomeMember
2024-01-01
2024-09-30
0000771999
DSS:NetInvestmentRevenueIncomeMember
2024-01-01
2024-09-30
0000771999
DSS:NetInvestmentIncomeMember
DSS:NetInvestmentRevenueIncomeMember
2023-01-01
2023-09-30
0000771999
DSS:NetInvestmentRevenueIncomeMember
2023-01-01
2023-09-30
0000771999
DSS:BMICapitalInternationalLLCMember
2023-01-01
2023-06-30
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:pure
DSS:Segments
utr:sqft
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
10-Q
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT
OF 1934
For
the quarterly period ended September 30, 2024
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT
OF 1934
001-32146
Commission
file number
DSS,
INC. |
(Exact
name of registrant as specified in its charter) |
New
York |
|
16-1229730 |
(State
or other Jurisdiction of
incorporation-
or Organization) |
|
(IRS
Employer
Identification
No.) |
275
Wiregrass Pkwy,
West
Henrietta, NY 14586
(Address
of principal executive offices)
(585)
325-3610
(Registrant’s
telephone number, including area code)
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes ☐ No ☒
Indicate
by check mark whether the registrant has submitted electronically every Interactive Date File required to be submitted pursuant to Rule
405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files) Yes ☒ No ☐
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See definitions of “large accelerated filer”, “accelerated filer”, “smaller
reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large
accelerated filer ☐ |
Accelerated
filer ☐ |
Non-accelerated
filer ☒ |
Smaller
reporting company ☒ |
Emerging
growth company ☐ |
|
|
|
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes ☐ No ☒
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Ticker
symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, $0.02 par value per share |
|
DSS |
|
The
NYSE American LLC |
As
of November 11, 2024 there were 7,066,772 shares of the registrant’s common stock, $0.02 par value, outstanding.
DSS,
INC.
FORM
10-Q
TABLE
OF CONTENTS
PART
I – FINANCIAL INFORMATION
ITEM
1 - FINANCIAL STATEMENTS
DSS,
INC. AND SUBSIDIARIES
Condensed
Consolidated Balance Sheets
| |
September 30, 2024 (unaudited) | | |
December 31, 2023
(restated) | |
ASSETS | |
| | | |
| | |
Current assets: | |
| | | |
| | |
Cash and cash equivalents | |
$ | 11,631,000 | | |
$ | 6,615,000 | |
Accounts receivable, net | |
| 2,653,000 | | |
| 3,994,000 | |
Inventory | |
| 3,307,000 | | |
| 2,819,000 | |
Assets held for sale | |
| 46,071,000 | | |
| 51,595,000 | |
Current portion of notes receivable | |
| 3,365,000 | | |
| 8,772,000 | |
Prepaid expenses and other current assets | |
| 1,779,000 | | |
| 839,000 | |
Total current assets | |
| 68,806,000 | | |
| 74,634,000 | |
| |
| | | |
| | |
Property, plant and equipment, net | |
| 5,860,000 | | |
| 6,417,000 | |
Investment in real estate, net | |
| 6,199,000 | | |
| 6,279,000 | |
Other investments | |
| 1,282,000 | | |
| 1,282,000 | |
Investment, equity method | |
| 131,000 | | |
| 128,000 | |
Marketable securities | |
| 7,263,000 | | |
| 9,979,000 | |
Notes receivable | |
| 254,000 | | |
| 111,000 | |
Other assets | |
| 133,000 | | |
| 97,000 | |
Right-of-use assets | |
| 6,654,000 | | |
| 7,210,000 | |
Goodwill | |
| 26,862,000 | | |
| 26,862,000 | |
Other intangible assets, net | |
| 19,213,000 | | |
| 20,193,000 | |
Total assets | |
$ | 142,657,000 | | |
$ | 153,192,000 | |
| |
| | | |
| | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | |
| | | |
| | |
| |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Accounts payable | |
$ | 3,399,000 | | |
$ | 3,654,000 | |
Accrued expenses and deferred revenue | |
| 2,411,000 | | |
| 2,511,000 | |
Other current liabilities | |
| 2,760,000 | | |
| 983,000 | |
Current portion of lease liability | |
| 638,000 | | |
| 686,000 | |
Current portion of long-term debt, net | |
| 49,873,000 | | |
| 47,776,000 | |
Total current liabilities | |
| 59,081,000 | | |
| 55,610,000 | |
| |
| | | |
| | |
Long-term debt, net | |
| 7,443,000 | | |
| 7,451,000 | |
Long term lease liability | |
| 6,454,000 | | |
| 6,917,000 | |
Total liabilities | |
| 72,979,000 | | |
| 69,978,000 | |
| |
| | | |
| | |
Commitments and contingencies (Note 12) | |
| - | | |
| - | |
| |
| | | |
| | |
Stockholders’ equity | |
| | | |
| | |
Preferred stock, $.02 par value; 47,000 shares authorized, zero shares issued and outstanding (zero on December 31, 2023); Liquidation value $1,000 per share, zero aggregate. zero on December 31, 2023). | |
| - | | |
| - | |
Common stock, $.02 par value; 200,000,000 shares authorized, 7,066,772 shares issued and outstanding (7,066,772 on December 31, 2023) | |
| 141,000 | | |
| 140,000 | |
Additional paid-in capital | |
| 322,189,000 | | |
| 319,963,000 | |
Accumulated deficit | |
| (270,210,000 | ) | |
| (256,176,000 | ) |
Total DSS stockholders’ equity | |
| 52,120,000 | | |
| 63,927,000 | |
Non-controlling interest in subsidiaries | |
| 17,559,000 | | |
| 19,287,000 | |
Total stockholders’ equity | |
| 69,679,000 | | |
| 83,214,000 | |
| |
| | | |
| | |
Total liabilities and stockholders’ equity | |
$ | 142,657,000 | | |
$ | 153,192,000 | |
See
accompanying notes to the condensed consolidated financial statements.
DSS,
INC. AND SUBSIDIARIES
Condensed
Consolidated Statements of Operations
(unaudited)
| |
| | |
| | |
| | |
| |
| |
For the Three Months Ended September 30, | | |
For the Nine Months Ended September 30, | |
| |
2024 | | |
2023 | | |
2024 | | |
2023
(restated) | |
Revenue: | |
| | | |
| | | |
| | | |
| | |
Printed products | |
$ | 4,828,000 | | |
$ | 3,315,000 | | |
$ | 11,429,000 | | |
$ | 12,976,000 | |
Rental income | |
| 496,000 | | |
| 236,000 | | |
| 1,334,000 | | |
| 3,464,000 | |
Net investment income | |
| 45,000 | | |
| 108,000 | | |
| 181,000 | | |
| 422,000 | |
Direct marketing | |
| - | | |
| 523,000 | | |
| - | | |
| 1,763,000 | |
Commission revenue | |
| 230,000 | | |
| - | | |
| 737,000 | | |
| 295,000 | |
Total revenue | |
| 5,599,000 | | |
| 4,182,000 | | |
| 13,681,000 | | |
| 18,920,000 | |
| |
| | | |
| | | |
| | | |
| | |
Costs and expenses: | |
| | | |
| | | |
| | | |
| | |
Cost of revenue | |
| 6,603,000 | | |
| 6,072,000 | | |
| 17,266,000 | | |
| 18,179,000 | |
Selling, general and administrative (including stock based compensation) | |
| 3,667,000 | | |
| 3,213,000 | | |
| 10,702,000 | | |
| 16,308,000 | |
Total costs and expenses | |
| 10,270,000 | | |
| 9,285,000 | | |
| 27,968,000 | | |
| 34,487,000 | |
Operating loss | |
| (4,671,000 | ) | |
| (5,103,000 | ) | |
| (14,287,000 | ) | |
| (15,567,000 | ) |
| |
| | | |
| | | |
| | | |
| | |
Other income (expense): | |
| | | |
| | | |
| | | |
| | |
Interest income | |
| 28,000 | | |
| 682,000 | | |
| 331,000 | | |
| 1,220,000 | |
Dividend income | |
| - | | |
| - | | |
| - | | |
| 12,000 | |
Other income (expense) | |
| 2,000 | | |
| (44,000 | ) | |
| 39,000 | | |
| 138,000 | |
Interest expense | |
| (53,000 | ) | |
| (51,000 | ) | |
| (242,000 | ) | |
| (438,000 | ) |
Foreign Currency Translation Adjustment | |
| 8,000 | | |
| - | | |
| (5,000 | ) | |
| - | |
(Loss) gain on equity method investment | |
| (4,000 | ) | |
| (6,000 | ) | |
| 3,000 | | |
| (28,000 | ) |
(Loss) gain on investments | |
| (449,000 | ) | |
| 301,000 | | |
| (1,021,000 | ) | |
| (2,471,000 | ) |
Impairment of assets upon deconsolidation | |
| - | | |
| - | | |
| - | | |
| (6,220,000 | ) |
Provision for loan losses | |
| (562,000 | ) | |
| (1,179,000 | ) | |
| (908,000 | ) | |
| (4,936,000 | ) |
(Loss) gain on sale of asset | |
| - | | |
| (1,281,000 | ) | |
| 165,000 | | |
| (1,281,000 | ) |
| |
| | | |
| | | |
| | | |
| | |
Income tax benefit (expense) | |
| - | | |
| - | | |
| 163,000 | | |
| (9,000 | ) |
Loss from continuing operations | |
| (5,701,000 | ) | |
| (6,681,000 | ) | |
| (15,762,000 | ) | |
| (29,580,000 | ) |
Loss from discontinued operations, net of tax | |
| - | | |
| - | | |
| - | | |
| (3,481,000 | ) |
Net loss | |
$ | (5,701,000 | ) | |
$ | (6,681,000 | ) | |
$ | (15,762,000 | ) | |
$ | (33,061,000 | ) |
| |
| | | |
| | | |
| | | |
| | |
Loss attributed to noncontrolling interest | |
| 418,000 | | |
| 2,339,000 | | |
| 1,728,000 | | |
| 2,736,000 | |
| |
| | | |
| | | |
| | | |
| | |
Net loss attributable to common stockholders | |
$ | (5,283,000 | ) | |
$ | (4,342,000 | ) | |
$ | (14,034,000 | ) | |
$ | (30,325,000 | ) |
| |
| | | |
| | | |
| | | |
| | |
Amounts attributable to DSS stockholders | |
| | | |
| | | |
| | | |
| | |
Loss from continuing operations net of taxes | |
| (5,283,000 | ) | |
| (4,342,000 | ) | |
| (14,034,000 | ) | |
| (27,033,000 | ) |
Loss from discontinued operations net of taxes | |
| - | | |
| - | | |
| - | | |
| (3,292,000 | ) |
Net loss attributable to DSS shareholders | |
$ | (5,283,000 | ) | |
$ | (4,342,000 | ) | |
$ | (14,034,000 | ) | |
$ | (30,325,000 | ) |
| |
| | | |
| | | |
| | | |
| | |
Loss per common share attributable to common stock holders - continuing operations | |
| | | |
| | | |
| | | |
| | |
Basic | |
$ | (0.75 | ) | |
$ | (0.62 | ) | |
$ | (1.99 | ) | |
$ | (3.87 | ) |
Diluted | |
$ | (0.75 | ) | |
$ | (0.62 | ) | |
$ | (1.99 | ) | |
$ | (3.87 | ) |
| |
| | | |
| | | |
| | | |
| | |
Loss per common share attributable to common stock holders - discontinued operations | |
| | | |
| | | |
| | | |
| | |
Basic | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | (0.47 | ) |
Diluted | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | (0.47 | ) |
| |
| | | |
| | | |
| | | |
| | |
Shares used in computing loss per common share: | |
| | | |
| | | |
| | | |
| | |
Basic | |
| 7,066,772 | | |
| 7,013,213 | | |
| 7,066,772 | | |
| 6,990,456 | |
Diluted | |
| 7,066,772 | | |
| 7,013,213 | | |
| 7,066,772 | | |
| 6,990,456 | |
See
accompanying notes to the condensed consolidated financial statements.
DSS,
INC. AND SUBSIDIARIES
Condensed
Consolidated Statements of Cash Flows
For
the Nine Months Ended September 30,
(unaudited)
| |
2024 | | |
2023 (restated) | |
Cash flows from operating activities: | |
| | | |
| | |
Net loss | |
$ | (15,762,000 | ) | |
$ | (33,061,000 | ) |
Loss from discontinued operations | |
| - | | |
| (3,481,000 | ) |
Loss from continuing operations | |
$ | (15,762,000 | ) | |
$ | (29,580,000 | ) |
Adjustments to reconcile net loss to net cash used by
operating activities: | |
| | | |
| | |
Depreciation and amortization | |
| 1,692,000 | | |
| 4,150,000 | |
Loss (income) on equity method investment | |
| (3,000 | ) | |
| 28,000 | |
Loss on investments | |
| 1,021,000 | | |
| 4,292,000 | |
Change in ROU assets | |
| 556,000 | | |
| 749,000 | |
(Loss) gain on sale of assets | |
| (165,000 | ) | |
| 1,281,000 | |
Impairment of assets upon deconsolidation | |
| - | | |
| 6,220,000 | |
Provision for loan losses | |
| 1,627,000 | | |
| 4,936,000 | |
Decrease (increase) in assets: | |
| | | |
| | |
Accounts receivable | |
| 1,557,000 | | |
| 2,520,000 | |
Inventory | |
| (488,000 | ) | |
| 4,368,000 | |
Prepaid expenses and other current assets | |
| (80,000 | ) | |
| 323,000 | |
Other assets | |
| (36,000 | ) | |
| 2,448,000 | |
Increase (decrease) in liabilities: | |
| | | |
| | |
Accounts payable | |
| (255,000 | ) | |
| (2,896,000 | ) |
Accrued expenses | |
| (111,000 | ) | |
| (15,549,000 | ) |
Change in ROU liabilities | |
| (511,000 | ) | |
| (763,000 | ) |
Other liabilities | |
| 1,777,000 | | |
| (81,000 | ) |
Net cash used by operating activities - continuing operations | |
| (9,181,000 | ) | |
| (17,554,000 | ) |
Net cash used by operating activities - discontinued operations | |
| - | | |
| (3,481,000 | ) |
Net cash used by operating activities | |
| (9,181,000 | ) | |
| (21,035,000 | ) |
| |
| | | |
| | |
Cash flows from investing activities: | |
| | | |
| | |
Purchase of property, plant and equipment | |
| (29,000 | ) | |
| (679,000 | ) |
Purchase of investment | |
| (1,861,000 | ) | |
| - | |
Disposal of property, plant and equipment | |
| 5,140,000 | | |
| 215,000 | |
Sale of marketable securities | |
| 3,029,000 | | |
| 11,330,000 | |
Issuance of new notes receivable, net origination fees | |
| (402,000 | ) | |
| (400,000 | ) |
Payments received on notes receivable | |
| 4,039,000 | | |
| 1,419,000 | |
Net cash provided by investing activities | |
| 9,916,000 | | |
| 11,885,000 | |
| |
| | | |
| | |
Cash flows from financing activities: | |
| | | |
| | |
Payments of long-term debt | |
| (1,492,000 | ) | |
| (4,056,000 | ) |
Borrowings of long-term debt | |
| 3,546,000 | | |
| 813,000 | |
Issuances of common stock, net of issuance costs | |
| 2,227,000 | | |
| - | |
Net cash provided (used) by financing activities | |
| 4,281,000 | | |
| (3,243,000 | ) |
| |
| | | |
| | |
Net increase (decrease) in cash - continuing operations | |
| 5,016,000 | | |
| (8,912,000 | ) |
Net increase (decrease) in cash - discontinued operations | |
| - | | |
| (3,481,000 | ) |
Cash and cash equivalents at beginning of period | |
| 6,615,000 | | |
| 19,290,000 | |
| |
| | | |
| | |
Cash and cash equivalents at end of period | |
$ | 11,631,000 | | |
$ | 6,897,000 | |
See
accompanying notes to the condensed consolidated financial statements.
DSS,
INC. AND SUBSIDIARIES
Condensed
Consolidated Statements of Changes in Stockholders’ Equity
(unaudited)
| |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| |
| |
Common
Stock | | |
Preferred
Stock | | |
Additional
Paid-
| | |
Accumulated | | |
Total
DSS | | |
Non-controlling
| | |
| |
| |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
in
Capital | | |
Deficit
(restated) | | |
Equity
(restated) | | |
Interest in
Subsidiary | | |
Total
(restated) | |
| |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| |
Balance, December
31, 2022 | |
| 6,950,858 | | |
$ | 139,000 | | |
| - | | |
$ | - | | |
$ | 319,766,000 | | |
$ | (194,343,000 | ) | |
$ | 125,562,000 | | |
$ | 31,119,000 | | |
$ | 156,681,000 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| - | | |
| | | |
| | |
Stock based payments | |
| 62,350 | | |
| 1,000 | | |
| - | | |
| - | | |
| 267,000 | | |
| - | | |
| 268,000 | | |
| - | | |
| 268,000 | |
Dividend in kind - Deconsolidation
of Sharing Services Global Corporation | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (1,206,000 | ) | |
| (1,206,000 | ) | |
| - | | |
| (1,206,000 | ) |
Deconsolidation of Sharing
Services | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| | | |
| - | | |
| 5,064,000 | | |
| 5,064,000 | |
Net loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (30,325,000 | ) | |
| (30,325,000 | ) | |
| (2,736,000 | ) | |
| (33,061,000 | ) |
Balance,
September 30, 2023 | |
| 7,013,208 | | |
$ | 140,000 | | |
| - | | |
$ | - | | |
$ | 320,033,000 | | |
$ | (225,874,000 | ) | |
$ | 94,299,000 | | |
$ | 33,447,000 | | |
$ | 127,746,000 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Balance, December 31, 2023 | |
| 7,066,772 | | |
$ | 140,000 | | |
| - | | |
$ | - | | |
$ | 319,963,000 | | |
$ | (256,176,000 | ) | |
$ | 63,927,000 | | |
$ | 19,287,000 | | |
$ | 83,214,000 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Initial public offering of
Impact BioMedical | |
| - | | |
| 1,000 | | |
| - | | |
| - | | |
| 2,226,000 | | |
| - | | |
| 2,227,000 | | |
| - | | |
| 2,227,000 | |
Net loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (14,034,000 | ) | |
| (14,034,000 | ) | |
| (1,728,000 | ) | |
| (15,762,000 | ) |
Balance,
September 30, 2024 | |
| 7,066,772 | | |
$ | 141,000 | | |
| - | | |
$ | - | | |
$ | 322,189,000 | | |
$ | (270,210,000 | ) | |
$ | 52,120,000 | | |
$ | 17,559,000 | | |
$ | 69,679,000 | |
See
accompanying notes to the condensed consolidated financial statements.
DSS,
INC. AND SUBSIDIARIES
NOTES
TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September
30, 2024
(Unaudited)
1.
Basis of Presentation and Significant Accounting Policies
The
Company, incorporated in the state of New York in May 1984 has conducted business in the name of DSS, Inc. On September 16, 2021, the
board of directors approved an agreement and plan of merger with a wholly owned subsidiary, DSS, Inc. (a New York corporation, incorporated
in August 2020), for the sole purpose of effecting a name change from Document Security Systems, Inc. to DSS, Inc. This change became
effective on September 30, 2021. DSS, Inc. maintained the same trading symbol “DSS”.
DSS,
Inc. (together with its consolidated subsidiaries, referred to herein as “DSS,” “we,” “us,” “our”
or the “Company”), currently operates nine (9) distinct business lines with operations and locations around the globe. These
business lines are: (1) Product Packaging, (2) Biotechnology, (3) Direct, (4) Commercial Lending, (5) Securities and Investment Management,
(6) Alternative Trading (7) Digital Transformation (discontinued in 2023), (8) Secure Living (discontinued in 2023), and (9) Alternative
Energy (discontinued in 2023). Each of these business lines are in different stages of development, growth, and income generation.
Our
divisions, their business lines, subsidiaries, and operating territories: (1) Our Product Packaging line is led by Premier Packaging
Corporation, Inc. (“Premier”), a New York corporation. Premier operates in the paper board and fiber based folding carton,
consumer product packaging, and document security printing markets. It markets, manufactures, and sells sophisticated custom folding
cartons, mailers, photo sleeves and complex 3-dimensional direct mail solutions. Premier is currently located in its new facility in
Rochester, NY, and primarily serves the US market. (2) The Biotechnology business line was created to invest in or acquire companies
in the BioHealth and BioMedical fields, including businesses focused on the advancement of drug discovery and prevention, inhibition,
and treatment of neurological, oncological, and immune related diseases. This division is also targeting unmet, urgent medical needs,
and is developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza.
(3) Direct Marketing, led by the holding corporation, Decentralized Sharing Systems, Inc. (“Decentralized”) provides services
to assist companies in the emerging growth “Gig” business model of peer-to-peer decentralized sharing marketplaces. Direct
Marketing’s products include, among other things, nutritional and personal care products sold throughout North America, Asia Pacific,
Middle East, and Eastern Europe. (4) Our Commercial Lending business division, driven by American Pacific Financial, Inc. (“APF”, formally American
Pacific Bancorp, Inc. “APB”), focused on acquiring equity positions in (i) undervalued
commercial bank(s), bank holding companies and nonbanking licensed financial companies operating in the United States, South East Asia,
Taiwan, Japan and South Korea, and (ii) companies engaged in—nonbanking activities closely related to banking, including loan syndication
services, mortgage banking, trust and escrow services, banking technology, loan servicing, equipment leasing, problem asset management,
SPAC (special purpose acquisition company) consulting services, and advisory capital raising services. (5) Securities and Investment
Management was established to develop and/or acquire assets in the securities trading or management arena, and to pursue, among other
product and service lines, broker dealers, and mutual funds management. Also in this segment is the Company’s real estate investment
trusts (“REIT”), organized for the purposes of acquiring hospitals and other acute or post-acute care centers from leading
clinical operators with dominant market share in secondary and tertiary markets, and leasing each property to a single operator under
a triple-net lease. the REIT was formed to originate, acquire, and lease a credit-centric portfolio of licensed medical real estate.
(6) Alternative Trading was established to develop and/or acquire assets and investments in the securities trading and/or funds management
arena. Alternative Trading, in partnership with recognized global leaders in alternative trading systems, intends to own and operate
in the US a single or multiple vertical digital asset exchanges for securities, tokenized assets, utility tokens, and cryptocurrency
via an alternative trading platform using blockchain technology. The scope of services within this section is planned to include asset
issuance and allocation (securities and cryptocurrency), FPO, IPO, ITO, PPO, and UTO listings on a primary market(s), asset digitization/tokenization
(securities, currency, and cryptocurrency), and the listing and trading of digital assets (securities and cryptocurrency) on a secondary
market(s). (7) Digital Transformation was established to be a Preferred Technology Partner and Application Development Solution for mid
cap brands in various industries including the direct selling and affiliate marketing sector. Digital improves marketing, communications
and operations processes with custom software development and implementation (discontinued in 2023). (8) The Secure Living division has
developed a plan for fully sustainable, secure, connected, and healthy living communities with homes incorporating advanced technology,
energy efficiency, and quality of life living environments both for new construction and renovations for single and multi-family residential
housing (discontinued in 2023). (9) The Alternative Energy group was established to help lead the Company’s future in the clean
energy business that focuses on environmentally responsible and sustainable measures. Alset Energy, Inc, the holding company for this
group, and its wholly owned subsidiary, Alset Solar, Inc., pursue utility-scale solar farms to serve US regional power grids and to provide
underutilized properties with small microgrids for independent energy (discontinued in 2023).
The
accompanying condensed consolidated financial statements contain all adjustments (consisting of normal recurring adjustments, unless
otherwise indicated) necessary to present fairly our consolidated financial position as of September 30, 2024 and December 31, 2023,
and the results of our consolidated operations for the interim periods presented. We follow the same accounting policies when preparing
quarterly financial data as we use for preparing annual data. These statements should be read in conjunction with the consolidated financial
statements and the notes included in our latest annual report on Form 10-K/A, for the fiscal year ended December 31, 2023 (“Form
10-K/A”), and our other reports on file with the Securities and Exchange Commission (the “SEC”).
Principles
of Consolidation - The consolidated financial statements include the accounts of DSS, Inc. and its subsidiaries. All significant
intercompany balances and transactions have been eliminated in consolidation.
Deconsolidation
of Sharing Services Global Corporation(“SHRG”) - On May 4, 2023, the Company distributed approximately 280 million
shares of SHRG beneficially held by DSS and Decentralized Sharing Systems in the form of a dividend to the shareholders of DSS common
stock. Upon completion of this distribution, DSS will retain an ownership interest in SHRG of approximately 7%. Immediately prior to
this distribution, DSS owned approximately 81% of the issued and outstanding common shares of SHRG. As a result, SHRG, whose operations
represented a significant portion of our Direct Marketing segment, was deconsolidated from our consolidated financial statements effective
as of May 1, 2023 (the “Deconsolidation”). The consolidated statement of operations for the fiscal quarter ended September
30, 2023, therefore includes one month of activity related to SHRG prior to the Deconsolidation. Subsequent to April 30, 2023 the assets
and liabilities of SHRG are no longer included within our consolidated balance sheets. Any discussions related to results, operations,
and accounting policies associated with SHRG refer to the periods prior to the Deconsolidation.
Upon
Deconsolidation, we recognized an impairment of assets due to the deconsolidation of SHRG approximately $6,220,000 which
is recorded as an impairment of assets due to the deconsolidation in our consolidated statements
of operations. Subsequent to the Deconsolidation, we accounted for our equity ownership interest in SHRG as a marketable security and
at the quoted price stock price of SHRG, valued at approximately $74,000 at December 31, 2023.
Use
of Estimates - The preparation of consolidated financial statements in conformity with accounting principles generally accepted
in the United States requires the Company to make estimates and assumptions that affect the amounts reported and disclosed in the financial
statements and the accompanying notes. Actual results could differ materially from these estimates. On an ongoing basis, the Company
evaluates its estimates, including those related to the accounts receivable, convertible notes receivable, inventory, fair values of
investments, intangible assets and goodwill, useful lives of intangible assets and property and equipment, fair values of options and
warrants to purchase the Company’s common stock, preferred stock, deferred revenue and income taxes, among others. The Company
bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which
form the basis for making judgments about the carrying values of assets and liabilities.
Reclassifications
- Cost associated with Professional fees for the three
and nine months ended September 30, 2023 and the nine months September 30, 2024 have been reclassified to Research and development to
conform with current period presentation.
Cash
Equivalents – All highly liquid investments with maturities of three months or less at the date of purchase are classified
as cash equivalents. Amounts included in cash equivalents in the accompanying consolidated balance sheets are money market funds whose
adjusted costs approximate fair value.
Accounts/Rents
Receivable - The Company extends credit to its customers in the normal course of business. The Company performs ongoing credit
evaluations and generally does not require collateral. Payment terms are generally 30 days but up to net 120 for certain customers. The
Company carries its trade accounts receivable at invoice amounts and its rent receivables at contract amounts, less an allowance for
credit losses. On a periodic basis, the Company evaluates its accounts receivable and establishes an allowance for credit losses based
upon management’s estimates that include a review of the history of past write-offs and collections and an analysis of current
credit conditions. In estimating expected losses in the accounts receivable portfolio, customer-specific financial data and macro-economic
assumptions are utilized to project losses over a reasonable and supportable forecast period. Assumptions and judgment are applied to
measure amounts and timing of expected future cash flows, collateral values and other factors used to determine the customers’
abilities to pay.
At
September 30, 2024, and December 31, 2023, the Company established a reserve for credit losses of approximately $2,497,000 and $2,494,000,
respectively. The Company does not accrue interest on past due accounts receivable.
Concentration
of Credit Risk - The Company maintains its cash in bank deposit accounts, which at times may exceed federally insured limits.
The Company believes it is not exposed to any significant credit risk because of any non-performance by the financial institutions. As
of September 30, 2024, two customers accounted for approximately 20% and 10% of our consolidated revenue and two customers accounted for
approximately 26% and 23% of our trade accounts receivable balance.
As
of September 30, 2023, one customer accounted for approximately 21% of our consolidated revenue and two customers accounted for approximately
32% and 15% of our consolidated trade accounts receivable balance.
As
of December 31, 2023, two customers accounted for approximately 20% and 11% of our consolidated revenue and 39% and 30% of our trade
accounts receivable balance.
Notes
receivable, unearned interest, and related recognition - The Company records all future payments of principal and interest on
notes as notes receivable, which are then offset by the amount of any related unearned interest income. For financial statement purposes,
the Company reports the net investment in the notes receivable on the consolidated balance sheet as current or long-term based on the
maturity date of the underlying notes. Such net investment is comprised of the amount advanced on the loans, adjusting for net deferred
loan fees or costs incurred at origination, amounts allocated to warrants received upon origination, and any payments received in advance.
The unearned interest is recognized over the term of the notes and the income portion of each note payment is calculated so as to generate
a constant rate of return on the net balance outstanding. Net deferred loan fees or costs, together with discounts recognized in connection
with warrants acquired at origination, are accreted as an adjustment to yield over the term of the loan.
Allowance
For Loans And Lease Losses - On January 1, 2022, the Company adopted amended accounting guidance “ASU No.2016-13 –
Credit Losses” which requires an allowance for credit losses to be deducted from the amortized cost basis of financial assets
to present the net carrying value at the amount that is expected to be collected over the contractual term of the asset considering relevant
information about past events, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported
amount. In estimating expected losses in the loan and lease portfolio, borrower-specific financial data and macro-economic assumptions
are utilized to project losses over a reasonable and supportable forecast period. Assumptions and judgment are applied to measure amounts
and timing of expected future cash flows, collateral values and other factors used to determine the borrowers’ abilities to repay
obligations. After the forecast period, the Company utilizes longer-term historical loss experience to estimate losses over the remaining
contractual life of the loans.
Investments
– Investments in equity securities with a readily determinable fair value, not accounted for under the equity method, are
recorded at fair value with unrealized gains and losses included in earnings. For equity securities without a readily determinable fair
value, the investment is recorded at cost, less any impairment, plus or minus adjustments related to observable transactions for the
same or similar securities, with unrealized gains and losses included in earnings. For equity method investments, the Company regularly
reviews its investments to determine whether there is a decline in fair value below book value. If there is a decline that is other-than-temporary,
the investment is written down to fair value. See Note 9 for further discussion on investments.
Fair
Value of Financial Instruments - Fair value is defined as the price that would be received to sell an asset or paid to
transfer a liability in an orderly transaction between market participants at the measurement date. The Fair Value Measurement Topic
of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) establishes a
three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to
unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable
inputs (Level 3 measurements). These tiers include:
●
Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets.
●
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted
prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active;
and
●
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions,
such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.
The
carrying amounts reported in the consolidated balance sheet of cash and cash equivalents, accounts receivable, prepaids, accounts payable
and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments. Marketable
securities classify as a Level 1 fair value financial instrument. The fair value of notes receivable approximates their carrying value
as the stated or discounted rates of the notes do not reflect recent market conditions. The fair value of revolving credit lines notes
payable and long-term debt approximates their carrying value as the stated or discounted rates of the debt reflect recent market conditions.
The fair value of investments where the fair value is not considered readily determinable, are carried at cost.
Inventory
– Inventories consist primarily of paper, pre-printed security paper, paperboard, fully prepared packaging, air filtration
systems, and health and beauty products which and are stated at the lower of cost or net realizable value on the first-in, first-out
(“FIFO”) method. Packaging work-in-process and finished goods included the cost of materials, direct labor and overhead.
At the closing of each reporting period, the Company evaluates its inventory in order to adjust the inventory balance for obsolete and
slow-moving items. An allowance for obsolescence of approximately $45,000 and $18,000 associated with the inventory at our Premier subsidiary
for September 30, 2024, and December 31, 2023, respectively. Write-downs and write-offs are charged to cost of revenue.
Investments
in real estate, net – Acquisition of assets are recorded at their relative fair value based on total accumulated costs
of the acquisition. Direct acquisition-related costs are capitalized as a component of the acquired assets. This includes all costs related
to finding, analyzing and negotiating a transaction. The allocation of the purchase price is an area that requires judgment and significant
estimates. Tangible and intangible assets include land, building and improvements, furniture, fixtures and equipment, acquired above
market and below market leases, in-place lease value (if applicable). Acquisition date fair values of assets and assumed liabilities
are determined based on replacement costs, appraised values, and estimated fair values using methods similar to those used by independent
appraisers and that use appropriate discount and/or capitalization rates and available market information. Depreciation and amortization
is computed using the straight-line method over the estimated useful lives of the assets. During 2023, the land and buildings related
to AMRE LifeCare and AMRE Winter Haven were reclassified to Assets held for sale.
Assets
held for sale – The Company has several buildings and the associated land they occupy for sale as of September 30, 2024
and December 31, 2023. These consist of primarily of retail space in Lindon, Utah approximating $5,593,000 (sale of this building was
finalized during Q2 2024) and the medical facilities associated with AMRE LifeCare of approximately $41,610,000 and AMRE Winter Haven
of approximately $4,396,000, and $65,000 of other assets.
Intangible
Assets - The estimated fair values of acquired intangibles are generally determined based upon future economic benefits such
as earnings and cash flows. Acquired identifiable intangible assets are recorded at fair value and are amortized over their estimated
useful lives. Acquired intangible assets with an indefinite life are not amortized but are reviewed for impairment at least annually
or more frequently whenever events or changes in circumstances indicate that the carrying amounts of those assets are below their estimated
fair values. Impairment is tested under ASC 350. At December 31, 2023, The Company impaired approximately $7,418,000 associated with
intangible assets for AMRE Lifecare and AMRE Winter Haven. No circumstances or events have occurred since the most recent analysis that
would indicate the need for an impairment is needed for the nine months ended September 30, 2024.
Goodwill
– Goodwill is the excess of cost of an acquired entity over the fair value of amounts assigned to assets acquired and liabilities
assumed in a business combination. Goodwill is subject to impairment testing at least annually and will be tested for impairment between
annual tests if an event occurs or circumstances change that would indicate the carrying amount may be impaired. FASB ASC Topic 350 provides
an entity with the option to first assess qualitative factors to determine whether the existence of events or circumstances leads to
a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, after completing
the assessment, it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying value,
the Company will proceed to a quantitative test. The Company may also elect to perform a quantitative test instead of a qualitative test
for any or all of our reporting units. The test compares the fair value of an entity’s reporting units to the carrying value of
those reporting units. This quantitative test requires various judgments and estimates. The Company estimates the fair value of the reporting
unit using a market approach in combination with a discounted operating cash flow approach. Impairment of goodwill is measured as the
excess of the carrying amount of goodwill over the fair values of recognized and unrecognized assets and liabilities of the reporting
unit. The Company performed its annual goodwill impairment test as of December 31, 2023, and no impairment was deemed necessary for the
goodwill associated with Premier Packaging Company, and Impact BioMedical of $1,769,000 and $25,093,000, respectively. The goodwill for
APB, and Sentinel Co. of approximately $29,744,000, and $1,234,000 respectively, were deemed impaired and written off at December 31,
2023. No circumstances or events have occurred since the most recent analysis that would indicate the need for an impairment is needed
for the nine months ended September 30, 2024.
Impairment
of Long-Lived Assets and Goodwill - The Company monitors the carrying value of long-lived assets for potential impairment and
tests the recoverability of such assets whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable.
If a change in circumstance occurs, the Company performs a test of recoverability by comparing the carrying value of the asset or asset
group to its undiscounted expected future cash flows. If cash flows cannot be separately and independently identified for a single asset,
the Company will determine whether impairment has occurred for the group of assets for which the Company can identify the projected cash
flows. If the carrying values are in excess of undiscounted expected future cash flows, the Company measures any impairment by comparing
the fair value of the asset or asset group to its carrying value.
Business
Combinations - Business combinations and non-controlling interests are recorded in accordance with FASB ASC 805 Business Combinations.
Under the guidance, the assets and liabilities of the acquired business are recorded at their fair values at the date of acquisition
and all acquisition costs are expensed as incurred. The excess of the purchase price over the estimated fair values is recorded as goodwill.
If the fair value of the assets acquired exceeds the purchase price and the liabilities assumed, then a gain on acquisition is recorded.
The application of business combination accounting requires the use of significant estimates and assumptions.
Loss
Per Common Share - The Company presents basic and diluted (loss) earnings per share. Basic (loss) earnings per share
reflect the actual weighted average of shares issued and outstanding during the period. Diluted (loss) earnings per share are
computed including the number of additional shares from outstanding warrants, stock options and preferred stock that would have been
outstanding if dilutive potential shares had been issued and is calculated utilizing the treasury stock method. In a loss period,
the calculation for basic and diluted (loss) earnings per share is the same, as the impact of potential common shares is
anti-dilutive. For the three and nine months ended September 30, 2023, potential dilutive instruments was 0.
For the three and nine months ended September 30, 2024, potential dilutive instruments was 0.
Income
Taxes - The Company recognizes estimated income taxes payable or refundable on income tax returns for the current year and for
the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income items is based
on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not
expected to be realized. We recognize penalties and accrued interest related to unrecognized tax benefits in income tax expense.
Going
Concern - The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a
going concern. This basis of accounting contemplates the recovery of our assets and the satisfaction of liabilities in the normal course
of business. These consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets
and liabilities, which might be necessary should we be unable to continue as a going concern. While the Company has approximately $11.6
million in cash, the Company has incurred operating losses as well as negative cash flows from operating and investing activities over
the past two years.
Aside
from its $11.6 million in cash as of September 30, 2024, the Company believes it can continue as a going concern, due to its ability
to generate operating cash through the sale of its $4.1 million of Marketable Securities. The Company has also taken steps to sell its
real estate holdings assets of AMRE LifeCare and Winter Haven located in Texas, Pennsylvania, and Florida. These properties approximate
$46.1 million in assets and are identified on the accompanying balance sheet as Held for sale. In addition, the Company has taken steps,
and will continue to take measures, to materially reduce the expenses and cash burn at all corporate and business line levels. Although
there are no assurances, we believe the above would allow us to fund our nine business lines current and planned operations for the twelve
months from the filing date of this Quarterly Report. Based on this, the Company has concluded that substantial doubt of its ability to
continue as a going concern has been alleviated.
Recently
Issued Accounting Pronouncements — In November 2023, the Financial Accounting Standards Board (“FASB”), issued
Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,
which improves reportable segment disclosure through enhanced disclosures about significant segment expenses. The amendment is effective
for fiscal years beginning after December 15, 2023 and for interim periods within fiscal years beginning after December 15, 2024 and
early adoption is permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements.
The Company has adopted the enhanced segment disclosures of the quarter ending September 30, 2024.
2.
Restatement of previously issued financial statements
The
Company has restated the financial statements for the year ended December 31, 2023 along with certain notes to such restated financial
statements. The adjustments recorded were related to the correction of an error identified by management. The nature and impact of this
adjustment on the Company’s previously issued financial statements is summarized as follows and the effects by impacted line items
are detailed in the tables below. Impacted amounts and associated disclosures are restated within the accompanying notes to the financial
statements.
On
May 4, 2023, the Company distributed approximately 280 million shares of Sharing Service Global Corporation (“SHRG”), beneficially
held by the Company, in the form of a dividend to the shareholders of the Company’s common stock. Upon completion of this distribution,
the Company retained an ownership interest in SHRG of approximately 7%. Effective May 1, 2023, SHRG was deconsolidated from the consolidated
financial statements (the “Deconsolidation”). The consolidated statement of operations does not include SHRG activity after
April 30, 2023 and the assets and liabilities of SHRG are no longer included within the Company’s consolidated balance sheet. In
the 10-Q for the second quarter of 2023, the Company recorded an approximate $29.9 million loss on deconsolidation. The Company also
recorded an decrease in accumulated deficit of $18.7 million to reflect the reversal of balances as of deconsolidation. In preparation
of the Form S-3 as well as the September 30, 2024 10-Q filing this transaction was revisited and it was determined that loss was unintentionally
overstated by approximately $23.5 million driven primarily by the increases in accumulated deficit that should have been recorded as
an offset to the initial income statement loss. In addition, the Company has determined that Deconsolidation also requires the recognition
of discontinued operations. Management and the Audit Committee of the Company has concluded that restatement of its December 31, 2023
financial statements, filed on March 27, 2024, was required.
The
following tables summarize the effect of the restatement on each financial statement line items as of the September 30, 2023:
Schedule
of Restatement
of Previously Issued Financial Statements
| |
As Previously Reported | | |
Adjustments | | |
As Restated | |
Consolidated Statements of Operations Income (Loss) for the nine months ended September 30, 2023 | |
| | | |
| | | |
| | |
Direct marketing revenue | |
$ | 6,088,000 | | |
| (4,325,000 | ) | |
$ | 1,763,000 | |
Total revenue | |
$ | 23,245,000 | | |
| (4,325,000 | ) | |
$ | 18,920,000 | |
Cost of revenue | |
$ | 19,437,000 | | |
| (1,258,000 | ) | |
$ | 18,179,000 | |
Selling, general and administrative (including stock based compensation) | |
$ | 21,036,000 | | |
| (4,728,000 | ) | |
$ | 16,308,000 | |
Total costs and expenses | |
$ | 40,473,000 | | |
| (5,986,000 | ) | |
$ | 34,487,000 | |
Operating loss | |
$ | (17,228,000 | ) | |
| (1,661,000 | ) | |
$ | (15,567,000 | ) |
Other income (expense) | |
$ | 139,000 | | |
| (1,000 | ) | |
$ | 138,000 | |
Loss on investment | |
$ | (30,490,000 | ) | |
| (28,019,000 | ) | |
$ | (2,471,000 | ) |
Impairment of assets due to deconsolidation | |
$ | - | | |
| 6,220,000 | | |
$ | (6,220,000 | ) |
Loss from continuing operations | |
$ | (53,030,000 | ) | |
| (23,450,000 | ) | |
$ | (29,580,000 | ) |
(Loss) from discontinued operations, net of tax | |
$ | - | | |
| 3,481,000 | | |
$ | (3,481,000 | ) |
Net loss | |
$ | (53,039,000 | ) | |
| (19,978,000 | ) | |
$ | (33,061,000 | ) |
Net loss attributable to common stockholders | |
$ | (50,303,000 | ) | |
| (19,978,000 | ) | |
$ | (30,325,000 | ) |
Loss per common share - basic earnings per share | |
$ | (7.20 | ) | |
| (3.33 | ) | |
$ | (3.87 | ) |
Loss per common share - diluted earnings per share | |
$ | (7.20 | ) | |
| (3.33 | ) | |
$ | (3.87 | ) |
Loss per common share - discontinued operations basic | |
$ | - | | |
| (0.47 | ) | |
$ | (0.47 | ) |
Loss per common share - discontinued operations diluted | |
$ | - | | |
| (0.47 | ) | |
$ | (0.47 | ) |
Consolidated Statements of Cash Flows for the nine months ended September 30, 2023 | |
| | | |
| | | |
| | |
Net loss | |
$ | (53,039,000 | ) | |
| (19,978,000 | ) | |
$ | (33,061,000 | ) |
Loss from discontinued operations | |
$ | - | | |
| (3,481,000 | ) | |
$ | (3,481,000 | ) |
Loss from continuing operations | |
$ | - | | |
| (29,580,000 | ) | |
$ | (29,580,000 | ) |
Loss (gain) on investments | |
$ | 30,490,000 | | |
| (26,198,000 | ) | |
$ | 4,292,000 | |
Impairment of assets | |
$ | - | | |
| 6,220,000 | | |
$ | 6,220,000 | |
Net cash used by operating activities - continuing operations | |
$ | - | | |
| (17,554,000 | ) | |
$ | (17,554,000 | ) |
Net cash used by operating activities - discontinued operations | |
$ | - | | |
| (3,481,000 | ) | |
$ | (3,481,000 | ) |
Net increase (decrease) in cash - continuing operations | |
$ | - | | |
| (8,912,000 | ) | |
$ | (8,912,000 | ) |
Net increase (decrease) in cash - discontinued operations | |
$ | - | | |
| (3,481,000 | ) | |
$ | (3,481,000 | ) |
Consolidated Statements of Changes in Stockholders’ Equity for the nine months ended September 30, 2023 | |
| | | |
| | | |
| | |
Dividend in kind - Deconsolidation of Sharing Services Global Corporation | |
$ | - | | |
| (1,206,000 | ) | |
$ | (1,206,000 | ) |
Deconsolidation of Sharing
Services Global Corp | |
$ | 18,773,000 | | |
| (18,773,000 | ) | |
$ | - | |
Net loss | |
$ | (50,303,000 | ) | |
| (19,978,000 | ) | |
$ | (30,325,000 | ) |
Accumulated deficit | |
$ | (225,873,000 | ) | |
| (1,000 | ) | |
$ | (225,874,000 | ) |
Total stockholders’ equity | |
$ | 127,747,000 | | |
| (1,000 | ) | |
$ | 127,746,000 | |
3.
Revenue
The
Company recognizes its revenue based on when the title passes to the customer or when the service is completed and accepted by the customer.
Revenue is measured as the amount of consideration the Company expects to receive in exchange for shipped product or service provided.
Sales and other taxes billed and collected from customers are excluded from revenue. The Company recognizes rental income associated
with its REIT, net of amortization of favorable/unfavorable lease terms relative to market and includes rental abatements and contractual
fixed increases attributable to operating leases, where collection has been considered probable, on a straight-line basis over the term
of the related lease. The Company recognizes net investment income from its investment banking line of business as interest and management
fees related to loans managed for third parties owed to the Company occurs. The Company generates revenue from its direct marketing line
of business primarily through internet sales and recognizes revenue as items are shipped.
As
of September 30, 2024, the Company had no unsatisfied performance obligations for contracts with an original expected duration of greater
than one year. Pursuant to Topic 606, the Company has applied the practical expedient with respect to disclosure of the deferral and
future expected timing of revenue recognition for transaction price allocated to remaining performance obligations. The Company elected
the practical expedient allowing it to not recognize as a contract asset the commission paid to its salesforce on the sale of its products
as an incremental cost of obtaining a contract with a customer but rather recognize such commission as expense when incurred as the amortization
period of the asset that the Company would have otherwise recognized is one year or less.
Sales Commissions
Sales
commissions are expensed as incurred for contracts with an expected duration of one year or less. There were no sales commissions capitalized
as of September 30, 2024 or September 30, 2023.
Shipping
and Handling Costs
Costs
incurred by the Company related to shipping and handling are included in cost of products sold. Amounts charged to customers relating
to these costs are reflected as revenue.
See
Note 16 for disaggregated revenue information.
4.
Inventory
Inventory
consisted of the following as of:
Schedule
of Inventory
| |
September | | |
December | |
| |
2024 | | |
2023 | |
Finished Goods | |
$ | 2,210,000 | | |
$ | 2,218,000 | |
Work in Process | |
| 489,000 | | |
| 180,000 | |
Raw Materials | |
| 653,000 | | |
| 439,000 | |
Inventory Gross | |
$ | 3,352,000 | | |
$ | 2,837,000 | |
Less allowance for obsolescence | |
| (45,000 | ) | |
| (18,000 | ) |
Inventory Net | |
$ | 3,307,000 | | |
$ | 2,819,000 | |
5.
Notes Receivable
Note
1
On
May 14, 2021, DSS Pure Air, Inc. a subsidiary of the Company entered a convertible promissory note (“Note 1”) with
Puradigm, Inc. (“Puradigm”), a company registered in the state of Texas. Note 1 has an aggregate principal balance up to
$5,000,000,
to be funded at the request of Puradigm. Note 1, which incurs interest at a rate of 6.65%
due quarterly, has a maturity date of May 1, 2023. Note
1 contains an optional conversion clause that allows the Company to convert all, or a portion of all, into newly issued member units
of Puradigm with the maximum principal amount equal to 18% of the total equity position of Puradigm at conversion. The
outstanding principal and interest as of September 30, 2024 and December 31, 2023, approximated $5,544,000
which is included in current notes receivable on the accompanying consolidated balance sheet. As of September 30, 2024 and December
31, 2023, the Company has a reserve of $3,326,000
and $2,772,000,
respectively, against the principal and interest outstanding.
Note
2
On
September 23, 2021, APB entered into refunding bond anticipatory note (“Note 2”) with Southeast Regional Management District (“SERMD”), which operates as a conservation
and reclamation district pursuant to Chapter 3891, Texas Special District Local Laws Code; Chapter 375, Texas Local Government Code;
and Chapter 49, Texas Water Code. The District Note was in the sum of $3,500,000 and incurs interest at a rate of 5.59% per annum. Principal
and interest are due in full on September 22, 2022, and later amended to extend the maturity date to September 19, 2024. The outstanding
principal and interest of $3,910,000 was included in the current portion of notes receivable on the consolidated balance sheet at December
31, 2023. Note 2 was repaid in full during March 2024.
Note
3
On
October 25, 2021, APF entered into a loan agreement (“Note 3”) with Asili, LLC. (“Asili”), a company
registered in the state of Utah. Note 3 has an initial aggregate principal balance up to $1,000,000,
to be funded at the request of Asili, with an option to increase the maximum principal borrowing to $3,000,000.
Note 3, which incurs interest at a rate of 8.0%
with principal and interest due at the maturity date of October
25, 2022. This note contains an optional conversion feature allowing APF to convert the outstanding principal to a 10%membership
interest. APF, as holder of Note 3, has the right to elect one member to the Board of Managers. This note is in default and the
outstanding principal and interest of approximately $884,000
was reserved for fully as of December 31, 2022.
Note
4
On
December 28, 2021, APF entered into a promissory note (“Note 4”) with WestPark Capital Group, LLC. (“WestPark”),
a company registered in the state of California. Note 4 has a principal balance of $700,000.
Note 4, which incurs interest at a rate of 12.0%
with principal and interest due at the maturity date of December 28, 2022. On December 29, 2022, the maturity date of this note was extended
to May
31, 2023. On November 27, 2023, the parties to
Note 4 agreed to modify the payment terms of the note to be monthly payments of $50,000
until the outstanding principal and interest
are paid in full. The outstanding principal and interest was paid in full as of September 30, 2024. At December 31, 2023 outstanding
principal and interest of $253,000
is included in the Current portion of notes receivable on the consolidated balance
sheet.
Note
5
On
January 24, 2022, APF and an individual entered into a promissory note (“Note 5”) in the principal sum of $100,000 with
interest of 6%,
due annually, and maturing in January
2024. The outstanding principal and interest
at September 30, 2024 and December 31, 2023 approximates $116,000 and
$103,000,
respectively, and is included in Current portion of notes receivable on the accompanying consolidate balance sheet. Note 5
was paid in full during October 2024.
Note
6
On
March 2, 2022, APF and WUURII Commerce, Inc. (“WUURII”), a corporation organized under the laws of the Republic of Korea entered into a promissory note (“Note
6”). Under the terms of Note 6, APF at its discretion, may lend up to the principal sum of $893,000 with an interest rate of 8%,
and matured in March 2024, with interest payable quarterly. The outstanding principal and interest at September 30, 2024 and December 31,
2023 is $484,000 and $446,000, respectively. This note has been extended to March 2025.
Note
7
On
May 9, 2022, DSS PureAir and Puradigm entered into a promissory note (“Note 7”) in the principal sum of $210,000
with interest of 10%,
is due in three quarterly installments beginning on August 9, 2022, with the first two payment consisting of interest only. All
unpaid principal and interest are due on February
9, 2023. This loan is currently in default and terms are currently being re-negotiated. The outstanding principal and
interest at September 30, 2024 and December 31, 2023 approximates $224,000
of which $134,00 and $112,000
has been reserved for as of September 30, 2024 and December 31, 2023, respectively, and is included in Current portions of notes
receivable on the accompanying consolidate balance sheet.
Note
8, related party
On
August 29, 2022, DSS Financial Management Inc and BMI Capital, Inc. (“BMIC”), a related party, entered into a promissory
note (“Note 8”) in the principal sum of $100,000
with interest of 8%,
is due in three quarterly installments beginning on September 14, 2022. All unpaid principal and interest is due on August
29, 2025. The outstanding principal and interest at September 30, 2024 approximated $86,000,
and was fully reserved for as of September 30, 2024. At December 31, 2023, the balance approximated $100,000
of which $76,000
is included in the Current portion of notes receivable and $24,000
is included in the long-term portion of notes receivable. DSS owns 24.9%
of the outstanding common shares of BMIC.
Note
9, related party
On
May 8, 2023, DSS Financial Management Inc and BMIC entered into a promissory note (“Note 9”) in the principal sum of
$102,000 with interest at the prime rate plus 2% (10.5% at September 30, 2024 and December 31, 2023) with a maturity date of May 7, 2026.
The outstanding principal and interest at September 30, 2024 approximated $110,000, and was fully reserved for as of September 30, 2024. At December
31, 2023 approximates $107,000 with approximately $53,000 of principal and accrued interest classified as Current portion notes receivable,
and the remaining balance of approximately $54,000 is recorded as notes receivable, on the accompanying consolidated balance sheet. DSS
owns 24.9% of the outstanding common shares of BMIC.
Note
10, related party
On
July 26, 2022, APF and VEII, Inc. (“VEII”) entered into a promissory note (“Note 10”) in the principal sum
of $1,000,000
with interest of 8%
with all unpaid principal and interest due on July
26, 2024. This note was amended so that all unpaid principal and interest is due July 26, 2025. The outstanding principal and
interest on September 30, 2024 approximates $959,000,
and is included in notes receivable on the accompanying consolidate balance sheet. Approximately $480,000
of Note 10 was reserved for as of March 31, 2024. No additional reserve was deemed necessary as of September 30, 2024. The
outstanding principal and interest on December 31, 2023, approximates $939,000,
net of $20,000
of unamortized origination fees and is included in notes receivable on the accompanying consolidate balance sheet. Heng Fai Ambrose
Chan, the Chairman of DSS, Inc is also the on the board of directors of VEII.
Note
11
On
February 19, 2021, Impact BioMedical, Inc, entered into a promissory note with an individual. The Company loaned the principal sum of
$206,000, with interest at a rate of 6.5%, and maturity date of August 19, 2022 later amended to February 19, 2026. Monthly payments
are due on the twenty-first day of each month and continuing each month thereafter until February 19, 2026. This note is secured by certain
real property situated in Collier County, Florida.
The
outstanding principal and interest as of September 30, 2024 and December 31, 2023, was approximately $202,000 and $203,000, respectively,
of which $143,000 is classified in Current notes receivable and the remaining $59,000 is classified as Notes receivable on the accompanying
consolidated balance sheet as of September 30, 2024. The outstanding principal and interest as of December 31, 2023 of approximately $203,000
is classified in Current notes receivable on the accompanying consolidated balance sheets.
Note
12
On
June 27, 2023, Decentralized Sharing Systems, Inc. and Stemtech Corporation (“Stemtech”) entered into a convertible promissory note (“Note 12”) in
the principal sum of $1,400,000 with
a discount of $300,000 and
interest rate of 10%
and maturity date of September
1, 2024. The outstanding principal,
interest, and associated discount was fully reserved for as of December 31, 2023.
Note
13
On
March 31,2023, DSS Biohealth Security, Inc and an individual entered into a promissory note (“Note 13”) in the principal
sum of $140,000 and
interest rate floating daily to Wall Street Journal Prime rate per annum (8.0%
at September 30, 2024 and 8.5% at December 31, 2023) with the total outstanding principal and interest due at the maturity date of March
31, 2025. The outstanding principal and
interest at December 31, 2023 approximates $133,000.
Of the total financed, approximately $99,000 of
principal and accrued interest is classified as Current portion of notes receivable and the remaining balance of approximately
$34,000 is
recorded as Notes receivable on the accompanying consolidated balance sheet at December 31, 2023. As of September 30, 2024, the
outstanding balance sheet approximating $135,000 was
fully reserved for.
Note 14
On August 29, 2024, APF entered
into a promissory note (“Note 14”) with WestPark. Note 14 has a principal balance of $459,000. Note 14, which incurs interest
at a rate of 10.0% with principal and interest due at the maturity date of April 27, 2026. On November 1, 2024, monthly payments of approximately
$28,000 are due with any unpaid interest and principal due at maturity. As of September 30,2024, the outstanding principal and interest
approximates $464,000, of which $305,000 is classified as Current notes receivable and the remaining $159,000 is classified as Notes receivable
on the accompanying consolidated balance sheet.
6.
Financial Instruments
Cash,
Cash Equivalents, Restricted Cash and Marketable Securities
The
following tables show the Company’s cash, cash equivalents, restricted cash, and marketable securities by significant investment
category as of:
Schedule
of Cash and Marketable Securities by Significant Investment Category
| |
September 30, 2024 | |
| |
cost | | |
Unrealized Gain/(Loss) | | |
Fair Value | | |
Cash and Cash Equivalents | | |
Marketable Securities | |
Cash | |
$ | 11,561,000 | | |
$ | - | | |
$ | 11,561,000 | | |
$ | 11,561,000 | | |
$ | - | |
Level 1 | |
| | | |
| | | |
| | | |
| | | |
| | |
Money Market Funds | |
| 70,000 | | |
| - | | |
| 70,000 | | |
| 70,000 | | |
| - | |
Marketable Securities | |
| 25,458,000 | | |
| (18,195,000 | ) | |
$ | 7,263,000 | | |
| - | | |
| 7,263,000 | |
Total | |
$ | 37,089,000 | | |
$ | (18,195,000 | ) | |
$ | 18,894,000 | | |
$ | 11,631,000 | | |
$ | 7,263,000 | |
| |
December 31, 2023 | |
| |
Adjusted Cost | | |
Unrealized Gain/(Loss) | | |
Fair Value | | |
Cash and Cash Equivalents | | |
Marketable Securities | |
Cash | |
$ | 6,545,000 | | |
$ | - | | |
$ | 6,545,000 | | |
$ | 6,545,000 | | |
$ | - | |
Level 1 | |
| | | |
| | | |
| | | |
| | | |
| | |
Money Market Funds | |
$ | 70,000 | | |
| - | | |
$ | 70,000 | | |
| 70,000 | | |
| - | |
Marketable Securities | |
$ | 27,304,000 | | |
| (17,325,000 | ) | |
$ | 9,979,000 | | |
| - | | |
| 9,979,000 | |
Total | |
$ | 33,919,000 | | |
$ | (17,325,000 | ) | |
$ | 16,594,000 | | |
$ | 6,615,000 | | |
$ | 9,979,000 | |
The
Company typically invests with the primary objective of minimizing the potential risk of principal loss. The Company’s investment
policy generally requires securities to be investment grade and limits the amount of credit exposure to any one issuer. Fair values were
determined for each individual security in the investment portfolio.
7.
Provision for Credit Losses
Effective
January 1, 2022, the Company adopted amended accounting guidance “ASU No.2016-13 – Credit Losses” for the measurement
of credit losses on financial instruments and other financial assets. That guidance requires an allowance for credit losses to be deducted
from the amortized cost basis of financial assets to present the net carrying value that is expected to be collected over the contractual
term of the assets considering relevant information about past events, current conditions, and reasonable and supportable forecasts that
affect the collectability of the reported amount. The guidance replaced the previous incurred loss model for determining the allowance
for credit losses.
Accounts
receivable are stated at the amount owed by the customer. The Company maintains an allowance for credit losses for accounts receivable
and unbilled receivables, based on expected credit losses resulting from the inability of our customers to make required payments. The
allowance for credit losses is estimated based on historical experience, current economic conditions and the creditworthiness of customers.
Receivables are charged to the allowance when determined to be no longer collectible. The Company regularly monitors and assesses its
risk of not collecting amounts owed by customers and records its allowance for credit losses based on the results of this analysis.
As
of September 30, 2024 and December 31, 2023, we have reviewed the entire loan portfolio as well as all financial assets of the Company for
the purpose of evaluating the loan portfolio and the loan balances, including a review of individual and collective portfolio loan quality,
loan(s) performance, including past due status and covenant defaults, assessment of the ability of the borrower to repay the loan on
the loan terms, whether any loans should be placed on nonaccrual or returned to accrual, any concentrations in any single borrower and/or
industry that we might need to further manage, and if any specific or general loan loss reserve should be established for the entire
loan portfolio or for any specific loan.
We
analyzed the loan loss reserve from three basis: general loan portfolio reserves; industry portfolio reserves, and specific loan loss
reserves. For the nine months ended September 30, 2024, and 2023, the Company recorded a Loan loss reserve of approximately $1,627,000 and $1,179,000,
respectively.
General
Loan Portfolio Reserve - Based upon the review of our loan portfolio, we do not believe that a substantial general loan
portfolio reserve is due at this time. However, we do recognize that some inherent risks are in all loan portfolios, thus we
recorded a general contingent portfolio reserve of $192,000
and $194,000
of the loan portfolio loan balance as of September 30, 2024 and December 31, 2023, respectively.
Industry
Portfolio Reserves - Given the relatively young loan portfolio and a diversification of the portfolio over several different loan
products, the risk is reduced. Accordingly, we have not recorded a discretionary reserve as of September 30, 2024 and December 31, 2023.
Specific
Loan Reserves - Previously, we had identified credit weaknesses and borrower repayment weakness with Asili, which has a current
principal and interest balance of $884,000
and have recorded a loan loss reserve for the full balance due the Company as of December 31, 2023 and September 30, 2024. The
Company had also previously identified credit weakness in Puradigm and has placed a reserve approximating $2,884,000
and $3,461,000 against the outstanding principal and interest as of December 31, 2023 and September 30, 2024, respectively.
Previously, the Company identified credit weakness in Stemtech and has placed a reserve approximating $1,045,000
against the outstanding principal and interest as of December 31, 2023 and September 30, 2024. During the first quarter of 2024, the
Company identified credit weakness in VEII and an individual and has placed a reserve approximating $479,000
and $135,000,
respectively, against the outstanding principal and interest as of March 31, 2024. Also during the first quarter of 2024, the
Company identified credit weakness in BMIC, a related party, and has placed a reserve approximating $211,000
against the outstanding principal and interest as of March 31, 2024, later adjusted to $196,000 as of September 30, 2024. No additional reserves were deemed necessary as of September 30, 2024.
8.
Disposal of assets
On
July 1st, 2023, The Company intended to sell its subsidiary, HWH World, Inc. to SHRG. The proposed transaction had the Company
sell 1,000 shares of common stock, representing all the issued and outstanding common stock shares of HWH World for the sum $706,000
representing the gross proceeds of the sale of HWH inventory less cost of goods sold. The parties involved amended the terms of this
agreement during the third quarter of 2023 from that of equity transaction to the purchase of inventory and assumption of certain liabilities
by SHRG. The amended agreement identified the purchase price approximating $758,000 to be paid from amongst other things, the gross proceeds
generated by the sale of the inventory acquired. The value of the inventory sold approximates $698,000 and the value of the liabilities
assumed by SHRG as part of this transaction is approximately $59,000. Further, the agreement includes payment of 1% royalty, starting
November 1, 2023, being defined as 1% of the gross sale price of all Seller’s new products made and sold outside of existing inventory
on the schedule, for a period ending October 31, 2033. There is substantial doubt regarding SHRG’s ability to sell and pay for
the inventory acquired, and therefore, the Company has determined not to record a receivable for the purchase price. A net loss approximating
$639,000 associated with this transaction has been recorded during the third quarter of 2023 and is included in Loss/Gain on sale of
assets on the consolidated statement of operations.
On
July 1st, 2023, The Company sold 100% of the equity in its subsidiary HWH Holdings, Inc, a Texas corporation (HWHH) to SHRG
for a purchase price approximating $259,000. This amount is to be paid from gross proceeds generated by the sale of the inventory acquired
as part of the transaction. This transaction was later amended during the third quarter of 2023 to assign the purchase of HWHH from SHRG
to Ascend Management Pte., Ltd. (“Ascend”), a Singaporean limited company. There is substantial doubt regarding Ascend’s
ability to sell and pay for the inventory acquired, and therefore, the Company has determined not to record a receivable for the purchase
price. A net loss approximating $617,000 associated with this transaction has been recorded during the third quarter of 2023 and is included
in Loss/Gain on sale of assets on the consolidated statement of operations.
On
June 13, 2024, the Company sold its retail space in Lindon, Utah for the sales price, net of expenses, of approximately $5,758,000. The
associated asset was previously classified as Held for sale in the amount of $5,593,000, resulting in a gain on the sale of approximately
$165,000.
9.
Investments
Alset
International Limited, related party
The
Company owns 127,179,291
shares or approximately 4%
of the outstanding shares of Alset International Limited (“Alset Intl”), a company incorporated in Singapore and publicly
listed on the Singapore Exchange Limited. This investment is classified as a marketable security and is classified as long-term assets
on the consolidated balance sheets as the Company has the intent and ability to hold the investments for a period of at least one year.
The Chairman of the Company, Mr. Heng Fai Ambrose Chan, is the Executive Director and Chief Executive Officer of Alset Intl. Mr. Chan
is also the majority shareholder of Alset Intl as well as the largest shareholder of the Company. The fair value of the marketable security
as of September 30, 2024 and December 31, 2023, was approximately $3,167,000
and $3,269,000,
respectively. During the nine months ended September 30, 2024 and 2023, the Company recorded unrealized loss of approximately $102,000
and $407,000,
respectively.
WestPark
Capital Group, LLC.
On
December 30, 2020, the Company signed a binding letter of intent with WestPark Capital Group, LLC. (“WestPark”) and
Century TBD, Inc. (“TBD”) where the parties agreed to prepare a note and stock exchange agreement whereby DSS will assign the TBD Note to WestPark and WestPark shall issue to DSS a stock certificate reflecting 7.5%
of the issued and outstanding shares of West Park. This note and stock exchange agreement was finalized during the first quarter
2022 and valued at approximately $500,000
and is included in Investments on the consolidated balance sheet on December 31, 2023 and as of September 30, 2024.
BMI
Capital International LLC, related party
On
September 10, 2020, the Company’s wholly owned subsidiary DSS Securities, Inc. entered into membership interest purchase agreement
with BMI Financial Group, Inc. a Delaware corporation (“BMIF”) and BMI Capital International LLC, a Texas limited liability
company (“BMIC”) whereas DSS Securities, Inc. purchased 14.9% membership interests in BMIC for $100,000. DSS Securities also
had the option to purchase an additional 10% of the outstanding membership interest which it exercised for $100,000 in January of 2021
and increased its ownership to 24.9%. The Company is currently accounting for this investment under the equity method of accounting per
ASC 323. The Company’s portion of net loss in BMIC during the nine months ended September 30, 2024 and 2023, approximated $3,000
and $28,000, respectively.
BMIC
is a broker-dealer registered with the Securities and Exchange Commission, is a member of the Financial Industry Regulatory Authority,
Inc. (“FINRA”), and is a member of the Securities Investor Protection Corporation (“SIPC”). The Company’s
chairman of the board and another independent board member of the Company also have ownership interest in BMIC.
BioMed
Technologies Asia Pacific Holdings Limited
On
December 19, 2020, Impact BioMedical, a wholly owned subsidiary of the Company, entered into a subscription agreement (the “Subscription
Agreement”) with BioMed Technologies Asia Pacific Holdings Limited (“BioMed”), a limited liability company incorporated
in the British Virgin Islands, pursuant to which the Company agreed to purchase 525 ordinary shares or 4.99% of BioMed at a purchase
price of approximately $632,000. The Subscription Agreement provides, among other things, the Company has the right to appoint a new
director to the board of BioMed. With respect to an issuance of shares to a third party by BioMed, the Company will have the right of
first refusal to purchase such shares, as well as customary tag-along rights. In connection with the Subscription Agreement, Impact Biomedical
entered into an exclusive distribution agreement (the “Distribution Agreement”) with BioMed, to directly market, advertise,
promote, distribute, and sell certain BioMed products, which focus on manufacturing natural probiotics, to resellers. This investment
is valued at cost as it does not have a readily determined fair value.
Under
the terms of the Distribution Agreement, the Company will have exclusive rights to distribute the products within the United States,
Canada, Singapore, Malaysia, and South Korea and non-exclusive distribution rights in all other countries. In exchange, the Company agreed
to certain obligations, including mutual marketing obligations to promote sales of the products. This agreement is for ten years with
a one year auto-renewal feature.
10.
Short-Term and Long-Term Debt
DSS,
Inc.
Promissory
Notes - On May 20, 2021, Premier Packaging entered into master loan and security agreement (“BOA Note”) with
Bank of America, N.A. (“BOA”) to secure financing approximating $3,710,000
to purchase and use as collateral, a new Heidelberg XL 106-7+L printing press. The aggregate principal balance outstanding under the
BOA Note shall bear interest at a variable rate on or before the loan closing. As of September 30, 2024, and December 31, 2023, the
outstanding principal on the BOA Note was $2,562,000
and $2,932,000,
respectively and had an interest rate of 4.63%.
As of September 30, 2024, $514,000
was included in the Current portion of long-term debt, net, and the remaining balance of approximately $2,049,000
is recorded as Long-term debt. As of December 31, 2023, $491,000
was included in the current portion of long-term debt, net, and the remaining balance of approximately $2,442,000
recorded as long-term debt. Interest expense equaled $96,000
and $0
for the nine months ended September 30, 2024 and 2023, respectively. The BOA Note contains certain covenants that are analyzed
annually. As of September 30, 2024, Premier is in compliance with these covenants.
On
August 1, 2021, AMRE Shelton, LLC., (“AMRE Shelton”) a subsidiary of AMRE, entered into a loan agreement (“Shelton
Agreement”) with Patriot Bank, N.A. (“Patriot Bank”) in an amount up to $6,155,000, with the amount financed approximating
$5,105,000. The Shelton Agreement contains monthly payments of principal and an initial interest of 4.25%. The interest will be adjusted
commencing on July 1, 2026 and continuing for the next succeeding 5-year period shall be determined one month prior to the change date
and shall be an interest rate equal to two hundred fifty (250) basis points above the Federal Home Loan Bank Boston 5-Year/25-Year amortizing
advance rate, but in no event less than 4.25% for the term of 120 months with a balloon payment approximating $2,829,000 due at term
end. The affective interest rate at September 30, 2024 was 4.25%. The funds borrowed were used to purchase a 40,000 square foot, 2.0 story,
Class A+ multi-tenant medical office building located on a 13.62-acre site, which serves as collateral for the Shelton Agreement. The
purchase price has been allocated as $4,640,000, $1,600,000, and $325,000 for the facility, land, and tenant improvements, respectively.
Also included in the value of the property is $585,000 of intangible assets with an estimated useful life of approximating 3 years. The
net book value of these assets as of September 30, 2024 approximated $6,199,000. Of the total financed, approximately $213,000 of principal
and accrued interest is classified as current portion of long-term debt, net, and the remaining balance of approximately $4,257,000 recorded
as long-term debt, net of $33,000 in deferred financing costs. Interest expense for the nine months ended September 30, 2024 and 2023 approximated
$147,000 and $153,000, respectively.
On
October 13, 2021, LVAM entered into loan agreement with BMIC (“BMIC Loan”), a related party, whereas LVAM borrowed the principal
amount of $3,000,000, with interest to be charged at a variable rate to be adjusted at the maturity date. The BMIC Loan matures on October
12, 2022, and contains an auto renewal period of three months. As of September 30, 2024 and December 31, 2023, $464,000 and $547,000, respectively,
are included in Current portion of long-term debt, net on the consolidated balance sheet.
On
October 13, 2021, LVAM entered into a loan agreement with Lee Wilson Tsz Kin (“Wilson Loan”), a related party, whereas LVAM
borrowed the principal amount of $3,000,000, with interest to be charged at a variable rate to be calculated at the maturity date. The
Wilson Loan matures on October 12, 2022, and contains an auto renewal period of nine months. As of September 30, 2024, $1,070,000 is included
in the Current portion of long-term debt, net on the consolidated balance sheet. As of December 31, 2023 $2,131,000 is included in the
Current portion of long-term debt, net on the consolidated balance sheet.
On
November 2, 2021, AMRE LifeCare entered into a loan agreement (“LifeCare Agreement”) with Pinnacle Bank,
(“Pinnacle Bank”) in the amount of $40,300,000.
The LifeCare Agreement supported the acquisition of three medical facilities located in Fort Worth, Texas, Plano, Texas, and
Pittsburgh, Pennsylvania for a purchase price of $62,000,000.
These assets are classified as investments, real estate on the consolidated balance sheet, and serves as collateral for the LifeCare
Agreement. The purchase price has been allocated as $32,100,000,
$12,100,000,
and $1,500,000 for
the facility, land and site improvements, respectively. Also included in the value of the property is $15,901,000 of
intangible assets with estimated useful lives ranging from 1 to 11 years.
The net book value of the assets acquired as of September 30, 2024 is approximately $41,570,000. The
LifeCare Agreement calls for the principal amount of the in equal, consecutive monthly installments based upon a twenty-five (25)
year amortization of the original principal amount of the LifeCare Agreement at an initial rate of interest equal to the interest
rate determined in accordance as of July 29, 2022 provided, however, such rate of interest shall not be less than 4.28%, with the
first such installment being payable on August 29, 2022 and subsequent installments being payable on the first day of each
succeeding month thereafter until the maturity date, at which time any outstanding principal and interest is due in
full. The affective interest rate at
September 30, 2024 was 9.5%.
As of December 31, 2023, the outstanding principal and interested approximates $41,331,000 and
is included in current portion of long-term debt, on the consolidated balance sheet. As of September 30, 2024, the outstanding
principal and interested approximates $45,147,000 and
is included in current portion of long-term debt, on the consolidated balance sheet. Interest expense for the nine months ended September
30, 2024 and 2023 approximated $2,939,000 and
$2,632,000,
respectively. This note is in default and demand was made for final payment to be made by December 22, 2023. This amount is past
due.
On
March 17, 2022, AMRE Winter Haven, LLC (“AMRE Winter Haven”) and Pinnacle Bank (“Pinnacle”) entered into a
term loan (“Pinnacle Loan”) whereas Pinnacle lent to AMRE Winter Haven the principal sum of $2,990,000,
maturing on March
7, 2024 (later extended to July 7, 2024) to acquire a medical facility located in Winter Haven, Florida for a purchase price
of $4,500,000.
The assets acquired are classified as investments, real estate on the consolidated balance sheet, and serves as collateral for the
Pinnacle Loan. The purchase price has been allocated as $3,200,000,
$1,000,000,
and $222,000
for the facility, land and site and tenant improvements, respectively. Also included in the value of the property is $29,000
of intangible assets with an estimated useful life of approximately 5
years. The net book value of the assets acquired as of September 30, 2024 is approximately $4,380,000.
Payments are to be made in equal, consecutive installments based on a 25-year
amortization period with interest at 4.28%.
The first installment is due January 1, 2023. This AMRE Winter Haven note is currently due, and has an effective interest rate of 9.6%.
The outstanding principal and interest, net of debt issuance costs of $17,000,
approximates $2,977,000
and is included in the current portion of long-term debt, net on the accompanying consolidated balance sheet at December 31, 2023.
The outstanding principal and interest, approximates $2,968,000
and is included in current portion of long-term debt, net on the accompanying consolidated balance sheet at September 30, 2024.
Interest expense equaled $179,000
and $185,000
for the nine months ended September 30, 2024 and 2023, respectively. This note was assumed by SMS Financial on August 15, 2024. This
note is in default and demand was made for final payment to be made by December 22, 2023. This amount is past due.
On
March 30, 2023, Premier Packaging, a subsidiary of the Company entered into a loan and security agreement with Union Bank & Trust
Company for the principal amount of $790,000 and shall accrued interest at the rate of 7.44%. Principal and interest shall be repaid
in the approximate amount of $14,000 through March 2029. This loan is collateralized by a Bobst Model Novacut and is guaranteed by DSS,
Inc. As of September 30, 2024, the outstanding principal and interest approximates $634,000 of which $121,000 was included in the current
portion of long-term debt, net, and the remaining balance of approximately $513,000 recorded as long-term debt. As of December 31, 2023,
the outstanding principal and interest approximates $719,000 of which $112,000 was included in the current portion of long-term debt,
net, and the remaining balance of approximately $607,000 recorded as long-term debt. Interest expense equaled $38,000 and $0 for the
nine months ended September 30, 2024 and
A
summary of scheduled principal payments of long-term debt, not including revolving lines of credit, subsequent to September 30, 2024,
are as follows:
Schedule of Notes Payable and Long-term Debt
Year | |
Amount | |
2024 | |
$ | 49,873,000 | |
2025 | |
| 858,000 | |
2026 | |
| 902,000 | |
2027 | |
| 948,000 | |
2028 | |
| 996,000 | |
Thereafter | |
| 3,739,000 | |
11.
Lease Liability
The
Company has operating leases predominantly for operating facilities. As of September 30, 2024, the remaining lease terms on our operating
leases range from less than one to twelve years. Renewal options to extend our leases have not been exercised due to uncertainty. Termination
options are not reasonably certain of exercise by the Company. There is no transfer of title or option to purchase the leased assets
upon expiration. There are no residual value guarantees or material restrictive covenants. There are no significant finance leases as
of September 30, 2024.
Future
minimum lease payments as of September 30, 2024 are as follows:
Maturity
of Lease Liability:
Schedule of Future Minimum Lease Payments
| |
Totals | |
2024 | |
| 240,000 | |
2025 | |
| 861,000 | |
2026 | |
| 839,000 | |
2027 | |
| 808,000 | |
2028 | |
| 824,000 | |
After | |
| 4,913,000 | |
Total lease payments | |
| 8,485,000 | |
Less: Imputed Interest | |
| (1,393,000 | ) |
Present value of remaining lease payments | |
$ | 7,092,000 | |
| |
| | |
Current | |
$ | 638,000 | |
Noncurrent | |
$ | 6,454,000 | |
| |
| | |
Weighted-average remaining lease term (years) | |
| 9.9 | |
| |
| | |
Weighted-average discount rate | |
| 4.1 | % |
Total
cash paid for leases during the nine months ended September 30, 2024 and 2023 approximated $786,000 and $931,000, respectively.
12.
Commitments and Contingencies
License
Agreement – On March 19, 2022, Impact BioMedical entered into a License Agreement (“Equivir License”) with
a third-party (“Licensee”) where the Licensor is granted the right, amongst other things, to develop, commercialize, and
sell the Company’s Equivir technology. In exchange, the Licensee shall pay the Company a royalty of 5.5% of net sales. Under the
terms of the Equivir Agreement, the Company shall reimburse the Licensee for 50% of the development costs provided that the development
costs shall not exceed $1,250,000. As of September 30, 2024 and December 31, 2023, $13,000 and $200,000, respectively, has been accrued for
in relation to the Equivir License as development of the Equivir technology.
13.
Stockholders’ Equity
Equity
transactions –
On
April 10, 2023, the Company issued 1,247,078 shares of common stock to Mr. Frank Heuszel, CEO of DSS, pursuant to his employment agreement.
These shares were issued to settle a previously recorded liability of approximately $268,000.
On
January 4, 2024 the Company effected a reverse stock split of 1 for 20. As of December 31, 2023 there were 140,264,240 shares of our
Common Stock issued and outstanding, which was converted to 7,066,772.
Stock-Based
Compensation –
The
Company records stock-based payment expense related to options and warrants based on the grant date fair value in accordance with FASB
ASC 718. Stock-based compensation includes expense charges for all stock-based awards to employees, directors, and consultants. Such
awards include option grants, warrant grants, and restricted stock awards. During the nine months ended September 30, 2024, there were none.
During the nine months ended September 30, 2023, the Company’s did not have stock compensation associated with these items, and 5,333
options were forfeited.
Impact
BioMedical, Inc. Equity Transactions –
On
May 10, 2023, the Company, the Company’s Board of Directors approved an amendment to the Articles of Incorporation of the Company
to increase the total number of shares of Common Stock to 4,000,000,000 shares with a par value of $0.001. Each share of Common Stock
when issued, shall have one (1) vote on all matters presented to the stockholders. Our Amended and Restated Articles of Incorporation
also authorized 100,000,000 shares of preferred stock, par value $0.001 per share. On May 11, 2023, the Company effected a forward split.
As a result, there were 3,877,282,251 shares of our Common Stock and no shares of preferred stock issued and outstanding. Prior to the
split, there were 125,073,621 shares of our Common Stock and no shares of preferred stock issued and outstanding. On October 31, 2023,
the Company effected a reverse stock split of 1 for 55. Also on October 31, 2023, DSS BioHealth Securities, Inc., the Company’s
largest shareholder converted 60,496,041 shares of Common Stock into 60,496,041 shares of Series A Convertible Preferred Shares, reducing
its ownership of the Company’s Common Stock from approximately 88% to approximately 12%. As of September 30, 2024 and December 31, 2023,
there were 11,503,955 and 10,000,000, respectively, shares of our Common Stock and 60,496,041 shares of preferred stock issued and outstanding.
On
August 8, 2023 DSS, the Company’s largest shareholder, distributed to its shareholders of record on July 10, 2023 4 shares of Impact
Bio’s stock for 1 share they owned. Each share of Impact BioMedical distributed as part of the distribution will not be eligible
for resale until 180 days from the date Impact BioMedical’s initial public offering becomes effective under the Securities Act,
subject to the discretion of the Company to lift the restriction sooner.
On October 31, 2023, the Company
effected a reverse stock split of 1 for 55. As of December 31, 2023, and December 31, 2022, there were 3,877,282,251 shares of our Common
Stock issued and outstanding which was converted to 70,496,041 shares. Also on October 31, 2023, DSS BioHealth Securities, Inc., the Company’s
largest shareholder converted 60,496,041 shares of Common Stock into 60,496,041 shares of Series A Convertible Preferred Shares, reducing
its ownership of the Company’s Common Stock from approximately 88% to approximately 12%.
On September 16, 2024,
Impact Biomedical Inc., entered into an underwriting agreement (the “Underwriting Agreement”) with Revere Securities,
LLC., as representative (the “Representative”) of the underwriters named therein (the “Underwriters”),
pursuant to which the Company agreed to sell to the Underwriters in a firm commitment initial public offering (the
“Offering”) an aggregate of 1,500,000
of the Company’s shares of common stock, par value $0.001
per share at a public offering price of $3.00
per share. On September 17, 2024, the Company closed the Offering, and as of September 30, 2024 there were 11,497,703
shares of common stock issued and outstanding. The total net proceeds to the Company from the Offering, after deducting discounts,
expenses allowance and expenses, was approximately $3,726,000
(inclusive of approximately $1.5 million contributed by DSS). A
final prospectus relating to this Offering was filed with the Commission on September 16, 2024. The shares of Common Stock were
approved to list on the NYSE American under the symbol “IBO” and began trading there on September 16, 2024. The Company
also issued warrants to the Representative and its affiliates (the “Representative’s Warrants”) warrants to
purchase the number of shares of Common Stock in the aggregate equal to 5% of the Common Stock to be issued and sold in this
offering (including any Shares of Common Stock sold upon exercise of the over-allotment option, if applicable). The
Representative’s Warrants are exercisable for a price per share equal to 125% of the public offering price. The warrants are
exercisable at any time, in whole or in part, commencing nine (9) months from the date of commencement of sales of the offering and
ending on the third anniversary thereof. As of September 30, 2024, only the 1,500,000
shares included in the Offering are freely tradable on the NYSE. The remaining outstanding common shares of Impact Biomedical of 9,997,703
are restricted from trading for 180 days from the Offering date.
14.
Discontinued Operations
On
May 4, 2023, the Company distributed approximately 280 million shares of SHRG beneficially held by DSS and Decentralized Sharing Systems
in the form of a dividend to the shareholders of DSS common stock. Upon completion of this distribution, DSS will retain an ownership
interest in SHRG of approximately 7%. Immediately prior to this distribution, DSS owned approximately 81% of the issued and outstanding
common shares of SHRG. As a result, SHRG, whose operations represented a significant portion of
our Direct Marketing segment, was deconsolidated from our consolidated financial statements effective as of May 1, 2023 (the “Deconsolidation”)
and will be treated as discontinued operations on the face of our financial statements. Subsequent to April 30, 2023, the assets and
liabilities of SHRG are no longer included within our consolidated balance sheets. Any discussions related to results, operations, and
accounting policies associated with SHRG refer to the periods prior to the Deconsolidation.
Upon
Deconsolidation, we recognized an impairment of assets due to the deconsolidation of SHRG approximately $6,220,000 which
is recorded as an impairment of assets due to the deconsolidation in our consolidated statements
of operations. Subsequent to the Deconsolidation, we accounted for our equity ownership interest in SHRG as a marketable security and
at the quoted price stock price of SHRG, valued at approximately $74,000 at December 31, 2023.
The
following tables show results of operations of the discontinued operation:
Schedule of Major Classes of Assets and Liabilities Held for Sale and Results of Operations
Sharing
Services Global Corporation
Statements
of Operations Loss - Discontinued Operations
For
the Nine Months Ended September 30,
| |
2023 | |
Revenue: | |
| | |
Direct marketing | |
$ | 4,325,000 | |
Total revenue | |
| 4,325,000 | |
| |
| | |
Costs and expenses: | |
| | |
Cost of revenue | |
| 2,055,000 | |
Selling, general and administrative | |
| 5,743,000 | |
Total costs and expenses | |
| 7,798,000 | |
Operating loss | |
| 3,473,000 | |
| |
| | |
Other income (expense): | |
| | |
Other income (expense) | |
| (96,000 | ) |
Interest income | |
| 6,000 | ) |
Gain (loss) on investments | |
| 82,000 | |
Impairment of assets | |
| - | |
Loss from discontinued operations before income taxes | |
| (3,481,000 | ) |
| |
| | |
Income tax benefit/(loss) | |
| - | |
Loss from discontinued operations | |
| (3,481,000 | ) |
15.
Supplemental Cash Flow Information
The
following table summarizes supplemental cash flows for the six months ended September 30, 2024 and 2023:
Schedule of Supplemental Cash Flow Information
| |
2024 | | |
2023 | |
| |
| | |
| |
Cash paid for interest | |
$ | 631,000 | | |
$ | 3,432,000 | |
Shares issued in lieu of cash bonus | |
| - | | |
| 268,000 | |
16.
Segment Information
The
Company’s nine businesses lines are organized, managed, and internally reported as five operating segments. One of these operating
segments, Product Packaging, is the Company’s packaging and printing group. Product Packaging operates in the paper board folding
carton, smart packaging, and document security printing markets. It markets, manufactures, and sells mailers, photo sleeves, sophisticated
custom folding cartons, and complex 3-dimensional direct mail solutions. These products are designed to provide functionality and marketability
while also providing counterfeit protection. A second, Biotechnology, invests in, or acquires companies in the biohealth and biomedical
fields, including businesses focused on the advancement of drug discovery and prevention, inhibition, and treatment of neurological,
oncological, and immune related diseases. This division is also developing open-air defense initiatives, which curb transmission of air-borne
infectious diseases, such as tuberculosis and influenza. Biotechnology is also targeting unmet, urgent medical needs. A third operating
segment, Securities, and Investment Management (“Securities”) was established to develop and/or acquire assets and investments
in the securities trading and/or funds management arena. Further, Securities, in partnership with recognized global leaders in alternative
trading systems, intends to own and operate in the US a single or multiple vertical digital asset exchanges for securities, tokenized
assets, utility tokens, stable coins and cryptocurrency via a digital asset trading platform using blockchain technology. The scope of
services within this section is planned to include asset issuance and allocation (securities and cryptocurrency), FPO, IPO, ITO, PPO,
STO and UTO listings on a primary market(s), asset digitization/tokenization (securities, currency, and cryptocurrency), and the listing
and trading of digital assets (securities and cryptocurrency) on a secondary market(s). Also in this segment is the Company’s real
estate investment trust (“REIT”), organized for the purposes of acquiring hospitals and other acute or post-acute care centers
from leading clinical operators with dominant market share in secondary and tertiary markets, and leasing each property to a single operator
under a triple-net lease. The REIT was formed to originate, acquire, and lease a credit-centric portfolio of licensed medical real estate.
The fourth segment, Direct, provides services to assist companies in the emerging growth gig business model of peer-to-peer decentralized
sharing marketplaces. It specializes in marketing and licensing its products and services through its subsidiary and partner network,
using the popular gig economic marketing strategy as a form of direct marketing. Direct marketing products include, among other things,
nutritional and personal care products sold throughout North America, Asia Pacific and Eastern Europe (see Note 1, Deconsolidation of
Sharing Services Global Corporation). The fifth business line, Commercial Banking, is organized for the purposes of being a financial
network holding company, focused providing commercial loans and on acquiring equity positions in (i) undervalued commercial bank(s),
bank holding companies and nonbanking licensed financial companies operating in the United States, South East Asia, Taiwan, Japan and
South Korea, and (ii) companies engaged in—nonbanking activities closely related to banking, including loan syndication services,
mortgage banking, trust and escrow services, banking technology, loan servicing, equipment leasing, problem asset management, SPAC (special
purpose acquisition company) consulting, and advisory capital raising services. From this financial platform, the Company shall provide
an integrated suite of financial services for businesses that shall include commercial business lines of credit, land development financing,
inventory financing, third party loan servicing, and services that address the financial needs of the world Gig Economy.
Approximate
information concerning the Company’s operations by reportable segment for the three and nine months ended September 30, 2024 and
2023 is as follows. The Company relies on intersegment cooperation and management does not represent that these segments, if operated
independently, would report the results contained herein:
Schedule of Operations by Reportable Segment
Three Months Ended September 30, 2024 | |
Product Packaging | | |
Commercial Lending | | |
Direct Marketing | | |
Biotechnology | | |
Securities | | |
Corporate | | |
Total | |
Revenue | |
$ | 4,846,000 | | |
$ | 45,000 | | |
$ | - | | |
$ | 1,000 | | |
$ | 707,000 | | |
$ | - | | |
$ | 5,599,000 | |
Cost of revenue | |
| 4,350,000 | | |
| 252,000 | | |
| (2,000 | ) | |
| 10,000 | | |
| 1,993,000 | | |
| - | | |
| 6,603,000 | |
Gross profit (loss) | |
| 496,000 | | |
| (207,000 | ) | |
| 2,000 | | |
| (9,000 | ) | |
| (1,286,000 | ) | |
| - | | |
| (1,004,000 | ) |
Operating expense | |
| 766,000 | | |
| 104,000 | | |
| 73,000 | | |
| 1,169,000 | | |
| 901,000 | | |
| 654,000 | | |
| 3,667,000 | |
Operating income (loss) | |
| (270,000 | ) | |
| (311,000 | ) | |
| (71,000 | ) | |
| (1,178,000 | ) | |
| (2,187,000 | ) | |
| (654,000 | ) | |
| (4,671,000 | ) |
Other income (expense) | |
| (43,000 | ) | |
| 251,000 | | |
| (52,000 | ) | |
| (573,000 | ) | |
| 336,000 | | |
| (949,000 | ) | |
| (1,030,000 | ) |
Three Months Ended September 30,2023 | |
Product Packaging | | |
Commercial Lending | | |
Direct Marketing | | |
Biotechnology | | |
Securities | | |
Corporate | | |
Total | |
Revenue | |
$ | 3,378,000 | | |
$ | 108,000 | | |
$ | 523,000 | | |
$ | - | | |
$ | 173,000 | | |
$ | - | | |
$ | 4,182,000 | |
Cost of revenue | |
| 3,871,000 | | |
| - | | |
| 271,000 | | |
| 4,000 | | |
| 1,926,000 | | |
| - | | |
| 6,072,000 | |
Gross profit (loss) | |
| (493,000 | ) | |
| 108,000 | | |
| 252,000 | | |
| (4,000 | ) | |
| (1,753,000 | ) | |
| - | | |
| (1,890,000 | ) |
Operating expense | |
| 647,000 | | |
| 139,000 | | |
| 55,000 | | |
| 1,154,000 | | |
| 352,000 | | |
| 866,000 | | |
| 3,213,000 | |
Operating income (loss) | |
| (1,140,000 | ) | |
| (31,000 | ) | |
| 197,000 | | |
| (1,158,000 | ) | |
| (2,105,000 | ) | |
| (866,000 | ) | |
| (5,103,000 | ) |
Other income (expense) | |
| (143,000 | ) | |
| 7,000 | | |
| (1,208,000 | ) | |
| 6,000 | | |
| (50,000 | ) | |
| (189,000 | ) | |
| (1,577,000 | ) |